chanch personal page - To The Moon

chanch

chanch

No personal profile

237Follow

6Followers

0Topic

0Badge

2021-07-27

Latest

Sorry, the original content has been removed

2021-08-29

Time to some challenge!

Sorry, the original content has been removed

2021-07-25

Reacted too slowly

Is IBM Stock Undervalued Or Overvalued? What To Consider

2021-08-10

Not a surprise!

3 Vaccine Stocks for the Next Decade

2021-09-19

Ok

Sorry, the original content has been removed

2021-07-28

Wow

Sorry, the original content has been removed

2021-07-17

Not for the faint hearted!

Sorry, the original content has been removed

2021-07-28

Stay calm people!

China state-owned daily urges calm after market rout

2021-07-25

More install for the year!

US IPO Week Ahead: 17 IPOs are coming

2021-07-25

Good

Sorry, the original content has been removed

2021-07-20

A whole new world!

Morgan Stanley: This Cycle Will Be "Hotter But Shorter" Than Usual

2021-07-19

Turbulent

Sorry, the original content has been removed

2022-03-14

No more booster jab pls!

Moderna Shares Soared Nearly 13% in Morning Trading

2021-07-28

Latest

Wall St snaps five-day up streak as caution rises before tech earnings, Fed

2021-07-23

Blood bath

Sorry, the original content has been removed

2021-07-22

$Tiger Brokers(TIGR)$ go go go

2021-07-20

Hmmmmm

AMC to reopen two of the top-grossing movie theaters in Los Angeles

2021-07-20

Recovering

U.S. stock main indexes rose more than 1%

2021-07-19

Will need to review

Sorry, the original content has been removed

2021-08-05

Settling time

Coursera fell 3% after soaring 21% yesterday

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3583728210057163","uuid":"3583728210057163","gmtCreate":1620638378496,"gmtModify":1621435601582,"name":"chanch","pinyin":"chanch","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":237,"tweetSize":46,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9010449813,"gmtCreate":1648458655734,"gmtModify":1676534340169,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Doesnt sound good","listText":"Doesnt sound good","text":"Doesnt sound good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9010449813","repostId":"1111470167","repostType":4,"repost":{"id":"1111470167","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648456625,"share":"https://ttm.financial/m/news/1111470167?lang=en_US&edition=fundamental","pubTime":"2022-03-28 16:37","market":"us","language":"en","title":"Piper Sandler Downgrades Beyond Meat Inc. to Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=1111470167","media":"Tiger Newspress","summary":"Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat","content":"<html><head></head><body><p>Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.</p><p><img src=\"https://static.tigerbbs.com/762434a1e8bad27e5d22b82244a85ed0\" tg-width=\"843\" tg-height=\"618\" width=\"100%\" height=\"auto\"/></p><p>Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Piper Sandler Downgrades Beyond Meat Inc. to Underweight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPiper Sandler Downgrades Beyond Meat Inc. to Underweight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-28 16:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.</p><p><img src=\"https://static.tigerbbs.com/762434a1e8bad27e5d22b82244a85ed0\" tg-width=\"843\" tg-height=\"618\" width=\"100%\" height=\"auto\"/></p><p>Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111470167","content_text":"Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).","news_type":1,"symbols_score_info":{"BYND":0.9}},"isVote":1,"tweetType":1,"viewCount":1943,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9032949328,"gmtCreate":1647266968723,"gmtModify":1676534209870,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"No more booster jab pls!&nbsp;","listText":"No more booster jab pls!&nbsp;","text":"No more booster jab pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032949328","repostId":"1186570327","repostType":4,"repost":{"id":"1186570327","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1647265373,"share":"https://ttm.financial/m/news/1186570327?lang=en_US&edition=fundamental","pubTime":"2022-03-14 21:42","market":"us","language":"en","title":"Moderna Shares Soared Nearly 13% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186570327","media":"Tiger Newspress","summary":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology com","content":"<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>&#34;Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,&#34; said Stephen Hoge, M.D., President of Moderna. &#34;This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.&#34;</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>&#34;It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,&#34; said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. &#34;We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.&#34;</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI&#39;s Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill &amp; Melinda Gates Foundation.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shares Soared Nearly 13% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shares Soared Nearly 13% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-14 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>&#34;Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,&#34; said Stephen Hoge, M.D., President of Moderna. &#34;This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.&#34;</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>&#34;It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,&#34; said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. &#34;We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.&#34;</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI&#39;s Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill &amp; Melinda Gates Foundation.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186570327","content_text":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).\"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,\" said Stephen Hoge, M.D., President of Moderna. \"This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.\"The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.\"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,\" said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. \"We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.\"The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887355448,"gmtCreate":1631981462884,"gmtModify":1676530682043,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887355448","repostId":"2168757119","repostType":4,"isVote":1,"tweetType":1,"viewCount":2460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887355513,"gmtCreate":1631981419632,"gmtModify":1676530682043,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887355513","repostId":"887339719","repostType":1,"repost":{"id":887339719,"gmtCreate":1631972463127,"gmtModify":1676530680476,"author":{"id":"35433028694349","authorId":"35433028694349","name":"老虎专刊","avatar":"https://static.laohu8.com/e0b93d50cf0df54ce7b1b746f78db36c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"35433028694349","idStr":"35433028694349"},"themes":[],"title":"【老虎週刊】老虎社區一週十大精華文章","htmlText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/888195652\" target=\"_blank\">《街頭智慧》：羅傑斯的反內卷投資人生</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3473459794537757\">@MidasMike</a> 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 <a href=\"https://laohu8.com/TW/885694539\" target=\"_blank\">都給IPhone13測評，我給股王蘋果做測評！</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3545995761422355\">@不二說價值</a> 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ <a href=\"https://laohu8.com/TW/881508993\" target=\"_blank\">buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法</a> 發佈者：","listText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/888195652\" target=\"_blank\">《街頭智慧》：羅傑斯的反內卷投資人生</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3473459794537757\">@MidasMike</a> 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 <a href=\"https://laohu8.com/TW/885694539\" target=\"_blank\">都給IPhone13測評，我給股王蘋果做測評！</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3545995761422355\">@不二說價值</a> 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ <a href=\"https://laohu8.com/TW/881508993\" target=\"_blank\">buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法</a> 發佈者：","text":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： 《街頭智慧》：羅傑斯的反內卷投資人生 發佈者：@MidasMike 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 都給IPhone13測評，我給股王蘋果做測評！ 發佈者：@不二說價值 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法 發佈者：","images":[{"img":"https://static.tigerbbs.com/3d5e2fc85108344477e4c0796d4f7359","width":"1717","height":"924"},{"img":"https://static.tigerbbs.com/99f2c14a32d644799c78e85ffdbce509","width":"755","height":"429"},{"img":"https://static.tigerbbs.com/a05c777fdd742a2cdc135436ad862e92","width":"928","height":"619"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887339719","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":12,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1943,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813819894,"gmtCreate":1630167062418,"gmtModify":1676530237453,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Time to some challenge!&nbsp;","listText":"Time to some challenge!&nbsp;","text":"Time to some challenge!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/813819894","repostId":"2162907389","repostType":4,"isVote":1,"tweetType":1,"viewCount":2391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896868203,"gmtCreate":1628569899302,"gmtModify":1703508301835,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Not a surprise!&nbsp;","listText":"Not a surprise!&nbsp;","text":"Not a surprise!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/896868203","repostId":"1181756731","repostType":4,"repost":{"id":"1181756731","kind":"news","pubTimestamp":1628563781,"share":"https://ttm.financial/m/news/1181756731?lang=en_US&edition=fundamental","pubTime":"2021-08-10 10:49","market":"us","language":"en","title":"3 Vaccine Stocks for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1181756731","media":"The Motley Fool","summary":"Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. W","content":"<p><i><b>Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?</b></i></p>\n<p>Over the last 18 months, COVID-19 has dominated the stock market in general, and vaccine stocks in particular. Companies and governments are trying to vaccinate as many people as possible to minimize the threat of this disease and maybe even eradicate it. That's the here and now, and any news can send vaccine stocks soaring, or crashing, overnight.</p>\n<p>It's hard to imagine what the vaccine stocks will look like 10 years from now. Will COVID-19 still be in the headlines? Or will it recede in importance? A group of Fool contributors suggest you might want to buy shares of&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>,&nbsp;<a href=\"https://laohu8.com/S/PFE\">Pfizer</a> , and&nbsp;<a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a>. Here's why.</p>\n<h3><b>This vaccine superstar will continue to outperform</b></h3>\n<p><b>Patrick Bafuma</b>&nbsp;<b>(Moderna):</b>&nbsp;Talk about setting a high bar with your first drug to market. With&nbsp;$20 billion in advance purchase agreements for 2021, Moderna's COVID-19 vaccine, Spikevax, is set to rival Humira for the best-selling drug in the world in 2021. Not to be proved a fluke, in 2022 this vaccine giant also has $12 billion in advance purchase agreements and another $8 billion in options for Spikevax.</p>\n<p>If there is one thing COVID-19 has demonstrated, it is that this disease is resilient. With New York City set to implement vaccine passports for gyms and indoor dining, other destinations may not be far behind. And with some employers and higher education programs starting to require vaccinations, not to mention the inevitable need for boosters, I believe the demand for jabs of the company's product, which just generated $4.4 billion in second-quarter revenue, will likely remain high.</p>\n<p>We already knew the COVID-19 vaccine was a boon for Moderna. And its flu vaccine is expected to be on the market in 2023 -- a market worth $5 billion to $6 billion annually. And you probably already knew that the mRNA specialist was working toward having a combination flu/respiratory syncytial virus/COVID-19 vaccination. Maybe you even knew that the company's $2 billion to $5 billion cytomegalovirus vaccine candidate is close to entering phase 3 trials. What you may not have known about is CEO Stéphane Bancel's long-term investment in oncology vaccines.</p>\n<p>The company has two exciting cancer vaccines in a 50-50 partnership with&nbsp;<a href=\"https://laohu8.com/S/MRK\">Merck</a> that I am keeping an eye on. These vaccines work by providing patients with an injection of mRNA that gets the patient's immune system to recognize specific abnormalities that are the hallmark of cancerous cells and then get the patient's own immune system to attack the cancer.</p>\n<p>The most advanced product of this collaboration, a \"personal cancer vaccine\" for head and neck squamous cell carcinoma, is currently in phase 2 trials. Thus far in its earlier trials, the treatment has a 50% response rate, more improvements in tumor burden over time, and longer progression-free survival than current standards of care.</p>\n<p>The other Merck-partnered oncology vaccine, while only in phase 1 trials, has a massive addressable market. This one targets mutations within the KRAS gene, with alterations of KRAS present in more than 20% of human cancers. With Moderna's KRAS vaccine covering 80% to 90% of KRAS mutations with its vaccine, this has potential to be another multi-billion-dollar treatment for the company.</p>\n<p>Yes, Spikevax will continue to be the company's cash cow. However, with $12.2 billion in cash and investments, and generating over $4 billion in revenue a quarter, the company has plenty of cash to fuel its research and development pipeline. If we're looking for an innovative vaccine maker to boost the portfolio of healthcare investors for the next 10 years, Moderna has lots of firepower in its pipeline, street credibility, and plenty of cash to make it all happen.</p>\n<h3><b>A $7-billion-a-year opportunity</b></h3>\n<p><b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;Although vaccines have long been a steady source of revenue for multiple big pharmas, investors have historically ignored the value of this particular product category -- that is, until the COVID-19 pandemic hit. The core reason is that vaccines, by and large, tend to be modest revenue generators for their manufacturers, with a few glaring exceptions such as&nbsp;<b>GlaxoSmithKline</b>'s Shingrix and Pfizer's blockbuster Prevnar franchise.</p>\n<p>Another issue is that vaccines have proven to be extremely difficult to develop for some of the most common viral agents. Respiratory syncytial virus, for example, is a seasonal illness that reportedly results in a whopping 58,000 hospitalizations per year in children younger than 5 and 177,000 in people over the age of 65, according to the Centers for Disease Control and Prevention. Yet there are still&nbsp;no fully protective vaccines&nbsp;approved for this large unmet medical need -- despite multiple attempts to develop such a vaccine over the past 60-plus years. Wall Street analysts, in turn, believe that the first company to achieve this lofty goal could be awarded with a product capable of generating over $7 billion per year in sales.</p>\n<p>Which big pharma has the inside track at breaking into this enormous market? As things stand right now, Pfizer is arguably sitting in the catbird seat with its RSV candidate known as RSVpreF. The company recently rolled out exceedingly impressive results for the vaccine in a midstage challenge study in adults under the age of 50. Pfizer has thus decided to advance RSVpreF into a critical phase 3 trial in adults, which is set to kick off next month. Top-line results from this global phase 3 trial ought to be available sometime in the first quarter of 2022.</p>\n<p>If this highly anticipated trial does indeed hit the mark, the pharma titan would almost certainly have its next superstar vaccine product -- possibly making its stock a great buy for long-term investors.</p>\n<h3><b>\"A world without infectious disease\"</b></h3>\n<p><b>Taylor Carmichael</b>&nbsp;<b>(Vir Biotechnology):</b>&nbsp;Vir Bio's mission statement -- \"creating a world without infectious disease\" -- is kind of amazing. If the biotech succeeds in eliminating infectious disease from the planet, it will be the most valuable healthcare company in the world.</p>\n<p>While it's hugely ambitious, it's not impossible. After all, we've largely eliminated some viral diseases like polio and smallpox. And it was vaccines that did it. What Vir is attempting to do, as&nbsp;I understand it, is use the breakthroughs in genomic research to find one-and-done vaccines for diseases like COVID-19, hepatitis B, influenza, and HIV. The company actually has four platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).</p>\n<p>We might ask why this vaccine company isn't a leader in&nbsp;COVID-19 vaccines.&nbsp;Vir Bio may or may not be in last place, but it's way back in the race. The company's vaccine, sotrovimab, is still in its<i>pre-clinical</i>phase.&nbsp;Meanwhile, the mRNA vaccines from Moderna and&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> have been on the market for months. The&nbsp;<a href=\"https://laohu8.com/S/NVAX\">Novavax</a> vaccine has suffered delays, but should be on the market soon. This is a remarkably quick pace, and shareholders of all three companies have been amply rewarded over the last 18 months.</p>\n<p><img src=\"https://static.tigerbbs.com/d0a1bd43968c51fecbafbb7569fc669f\" tg-width=\"720\" tg-height=\"500\" referrerpolicy=\"no-referrer\">NVAXDATA BY&nbsp;YCHARTS</p>\n<p>Compared to the 5,000% return of Novavax, or the 2,000% return of Moderna, or the 1,000% jump BioNTech investors have received, Vir's 200% gain is a little disappointing. (On the other hand, Vir shareholders did six times better than people who invested in an index fund.)</p>\n<p>The main reason Novavax, Moderna, and BioNTech have soared is that all three companies focused on the spike protein of the coronavirus. This has been incredibly successful, creating large numbers of antibodies. If a vaccine produces a large enough level of antibodies, it wards off the disease and keeps people from getting infected.</p>\n<p>What about the future, and all the mutating strains? Historically, the way vaccine companies dealt with mutation in the past, like with the flu, was to vaccinate people again and again. You vaccinate for the known strains and hope the drug will produce enough antibodies and T cells to ward off mutating strains as well. That's why both Novavax and Moderna are pursuing a&nbsp;flu/COVID-19 combo shot&nbsp;-- the plan is for people to take it every year.</p>\n<p>That plan might come to a crashing halt if Vir succeeds with its one-and-done vaccine. While Vir might seem too far back in the race to make any difference, the company has an ace up its sleeve. The Food and Drug Administration has given the company an Emergency Use Authorization to market sotrovimab not as a vaccine, but as a treatment for people who have already been infected with COVID-19. So investors will have real-world data about how the company's drug works.</p>\n<p>Of course the COVID-19 treatment market is vastly smaller than the vaccine market. But what makes Vir so interesting is the company's ultimate focus. Its mission is to eliminate infectious disease from the planet. Today, you might invest in Vir for its COVID-19 treatment. But what's really exciting are the vaccines the company hopes to introduce over the next decade. If Vir successfully removes one major illness from the world, investors will make a lot of money.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Vaccine Stocks for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Vaccine Stocks for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?\nOver the last 18 months, COVID-19 has dominated ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","MRNA":"Moderna, Inc.","MRK":"默沙东","BNTX":"BioNTech SE","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181756731","content_text":"Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?\nOver the last 18 months, COVID-19 has dominated the stock market in general, and vaccine stocks in particular. Companies and governments are trying to vaccinate as many people as possible to minimize the threat of this disease and maybe even eradicate it. That's the here and now, and any news can send vaccine stocks soaring, or crashing, overnight.\nIt's hard to imagine what the vaccine stocks will look like 10 years from now. Will COVID-19 still be in the headlines? Or will it recede in importance? A group of Fool contributors suggest you might want to buy shares of Moderna, Inc., Pfizer , and Vir Biotechnology, Inc.. Here's why.\nThis vaccine superstar will continue to outperform\nPatrick Bafuma (Moderna): Talk about setting a high bar with your first drug to market. With $20 billion in advance purchase agreements for 2021, Moderna's COVID-19 vaccine, Spikevax, is set to rival Humira for the best-selling drug in the world in 2021. Not to be proved a fluke, in 2022 this vaccine giant also has $12 billion in advance purchase agreements and another $8 billion in options for Spikevax.\nIf there is one thing COVID-19 has demonstrated, it is that this disease is resilient. With New York City set to implement vaccine passports for gyms and indoor dining, other destinations may not be far behind. And with some employers and higher education programs starting to require vaccinations, not to mention the inevitable need for boosters, I believe the demand for jabs of the company's product, which just generated $4.4 billion in second-quarter revenue, will likely remain high.\nWe already knew the COVID-19 vaccine was a boon for Moderna. And its flu vaccine is expected to be on the market in 2023 -- a market worth $5 billion to $6 billion annually. And you probably already knew that the mRNA specialist was working toward having a combination flu/respiratory syncytial virus/COVID-19 vaccination. Maybe you even knew that the company's $2 billion to $5 billion cytomegalovirus vaccine candidate is close to entering phase 3 trials. What you may not have known about is CEO Stéphane Bancel's long-term investment in oncology vaccines.\nThe company has two exciting cancer vaccines in a 50-50 partnership with Merck that I am keeping an eye on. These vaccines work by providing patients with an injection of mRNA that gets the patient's immune system to recognize specific abnormalities that are the hallmark of cancerous cells and then get the patient's own immune system to attack the cancer.\nThe most advanced product of this collaboration, a \"personal cancer vaccine\" for head and neck squamous cell carcinoma, is currently in phase 2 trials. Thus far in its earlier trials, the treatment has a 50% response rate, more improvements in tumor burden over time, and longer progression-free survival than current standards of care.\nThe other Merck-partnered oncology vaccine, while only in phase 1 trials, has a massive addressable market. This one targets mutations within the KRAS gene, with alterations of KRAS present in more than 20% of human cancers. With Moderna's KRAS vaccine covering 80% to 90% of KRAS mutations with its vaccine, this has potential to be another multi-billion-dollar treatment for the company.\nYes, Spikevax will continue to be the company's cash cow. However, with $12.2 billion in cash and investments, and generating over $4 billion in revenue a quarter, the company has plenty of cash to fuel its research and development pipeline. If we're looking for an innovative vaccine maker to boost the portfolio of healthcare investors for the next 10 years, Moderna has lots of firepower in its pipeline, street credibility, and plenty of cash to make it all happen.\nA $7-billion-a-year opportunity\nGeorge Budwell (Pfizer): Although vaccines have long been a steady source of revenue for multiple big pharmas, investors have historically ignored the value of this particular product category -- that is, until the COVID-19 pandemic hit. The core reason is that vaccines, by and large, tend to be modest revenue generators for their manufacturers, with a few glaring exceptions such as GlaxoSmithKline's Shingrix and Pfizer's blockbuster Prevnar franchise.\nAnother issue is that vaccines have proven to be extremely difficult to develop for some of the most common viral agents. Respiratory syncytial virus, for example, is a seasonal illness that reportedly results in a whopping 58,000 hospitalizations per year in children younger than 5 and 177,000 in people over the age of 65, according to the Centers for Disease Control and Prevention. Yet there are still no fully protective vaccines approved for this large unmet medical need -- despite multiple attempts to develop such a vaccine over the past 60-plus years. Wall Street analysts, in turn, believe that the first company to achieve this lofty goal could be awarded with a product capable of generating over $7 billion per year in sales.\nWhich big pharma has the inside track at breaking into this enormous market? As things stand right now, Pfizer is arguably sitting in the catbird seat with its RSV candidate known as RSVpreF. The company recently rolled out exceedingly impressive results for the vaccine in a midstage challenge study in adults under the age of 50. Pfizer has thus decided to advance RSVpreF into a critical phase 3 trial in adults, which is set to kick off next month. Top-line results from this global phase 3 trial ought to be available sometime in the first quarter of 2022.\nIf this highly anticipated trial does indeed hit the mark, the pharma titan would almost certainly have its next superstar vaccine product -- possibly making its stock a great buy for long-term investors.\n\"A world without infectious disease\"\nTaylor Carmichael (Vir Biotechnology): Vir Bio's mission statement -- \"creating a world without infectious disease\" -- is kind of amazing. If the biotech succeeds in eliminating infectious disease from the planet, it will be the most valuable healthcare company in the world.\nWhile it's hugely ambitious, it's not impossible. After all, we've largely eliminated some viral diseases like polio and smallpox. And it was vaccines that did it. What Vir is attempting to do, as I understand it, is use the breakthroughs in genomic research to find one-and-done vaccines for diseases like COVID-19, hepatitis B, influenza, and HIV. The company actually has four platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).\nWe might ask why this vaccine company isn't a leader in COVID-19 vaccines. Vir Bio may or may not be in last place, but it's way back in the race. The company's vaccine, sotrovimab, is still in itspre-clinicalphase. Meanwhile, the mRNA vaccines from Moderna and BioNTech SE have been on the market for months. The Novavax vaccine has suffered delays, but should be on the market soon. This is a remarkably quick pace, and shareholders of all three companies have been amply rewarded over the last 18 months.\nNVAXDATA BY YCHARTS\nCompared to the 5,000% return of Novavax, or the 2,000% return of Moderna, or the 1,000% jump BioNTech investors have received, Vir's 200% gain is a little disappointing. (On the other hand, Vir shareholders did six times better than people who invested in an index fund.)\nThe main reason Novavax, Moderna, and BioNTech have soared is that all three companies focused on the spike protein of the coronavirus. This has been incredibly successful, creating large numbers of antibodies. If a vaccine produces a large enough level of antibodies, it wards off the disease and keeps people from getting infected.\nWhat about the future, and all the mutating strains? Historically, the way vaccine companies dealt with mutation in the past, like with the flu, was to vaccinate people again and again. You vaccinate for the known strains and hope the drug will produce enough antibodies and T cells to ward off mutating strains as well. That's why both Novavax and Moderna are pursuing a flu/COVID-19 combo shot -- the plan is for people to take it every year.\nThat plan might come to a crashing halt if Vir succeeds with its one-and-done vaccine. While Vir might seem too far back in the race to make any difference, the company has an ace up its sleeve. The Food and Drug Administration has given the company an Emergency Use Authorization to market sotrovimab not as a vaccine, but as a treatment for people who have already been infected with COVID-19. So investors will have real-world data about how the company's drug works.\nOf course the COVID-19 treatment market is vastly smaller than the vaccine market. But what makes Vir so interesting is the company's ultimate focus. Its mission is to eliminate infectious disease from the planet. Today, you might invest in Vir for its COVID-19 treatment. But what's really exciting are the vaccines the company hopes to introduce over the next decade. If Vir successfully removes one major illness from the world, investors will make a lot of money.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"BNTX":0.9,"MRNA":0.9,"VIR":0.9,"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":2583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896868980,"gmtCreate":1628569860940,"gmtModify":1703508300862,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Oh wow!&nbsp;","listText":"Oh wow!&nbsp;","text":"Oh wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896868980","repostId":"1186259544","repostType":4,"isVote":1,"tweetType":1,"viewCount":2271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899837205,"gmtCreate":1628172944607,"gmtModify":1703502574255,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Settling time&nbsp;","listText":"Settling time&nbsp;","text":"Settling time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899837205","repostId":"1132594719","repostType":4,"repost":{"id":"1132594719","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628171470,"share":"https://ttm.financial/m/news/1132594719?lang=en_US&edition=fundamental","pubTime":"2021-08-05 21:51","market":"us","language":"en","title":"Coursera fell 3% after soaring 21% yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1132594719","media":"Tiger Newspress","summary":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial r","content":"<p>(Aug 5)&nbsp;Coursera fell 3% after soaring 21% yesterday.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have&nbsp;reported Q2 2021 financial results that look \"mixed\" in the extreme&nbsp;yesterday&nbsp;.</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coursera fell 3% after soaring 21% yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoursera fell 3% after soaring 21% yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 5)&nbsp;Coursera fell 3% after soaring 21% yesterday.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have&nbsp;reported Q2 2021 financial results that look \"mixed\" in the extreme&nbsp;yesterday&nbsp;.</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COUR":"Coursera, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132594719","content_text":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .\nOn the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.\nWait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.\nWhen analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.\nSo in the case of Coursera, analysts forecast that the company would lose $0.11 per sharepro forma.But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company'sGAAPloss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company'spro formaloss for the quarter was only $0.05 per share.\nOr in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"","news_type":1,"symbols_score_info":{"COUR":0.9}},"isVote":1,"tweetType":1,"viewCount":2656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890077515,"gmtCreate":1628071841737,"gmtModify":1703500663435,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Roller coaster ride!&nbsp;","listText":"Roller coaster ride!&nbsp;","text":"Roller coaster ride!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890077515","repostId":"1120792298","repostType":4,"isVote":1,"tweetType":1,"viewCount":2158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801981924,"gmtCreate":1627479524768,"gmtModify":1703490752094,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801981924","repostId":"1102507343","repostType":4,"isVote":1,"tweetType":1,"viewCount":1754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803214280,"gmtCreate":1627441195740,"gmtModify":1703490029802,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Stay calm people!&nbsp;","listText":"Stay calm people!&nbsp;","text":"Stay calm people!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/803214280","repostId":"2154943718","repostType":4,"repost":{"id":"2154943718","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627440754,"share":"https://ttm.financial/m/news/2154943718?lang=en_US&edition=fundamental","pubTime":"2021-07-28 10:52","market":"hk","language":"en","title":"China state-owned daily urges calm after market rout","url":"https://stock-news.laohu8.com/highlight/detail?id=2154943718","media":"Reuters","summary":"SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday aft","content":"<p>SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday after investors dumped mainland shares for a second day on worries over the impact of tighter government regulations.</p>\n<p>Regulatory moves aimed at the education, property and technology sectors sparked heavy selling this week in Chinese markets, and have left global investors bruised and uncertain over the outlook for investments in Chinese firms.</p>\n<p>In a front page commentary on Wednesday, the state-owned Securities Times said that systemic risks \"do not exist in the A-share market overall.\"</p>\n<p>\"The macroeconomy is still in a steady rebound stage, and short-term fluctuations do not change the long-term positive outlook for A-shares,\" the commentary said.</p>\n<p>\"The recent market decline to some extent reflects misinterpretation of policies and a venting of emotion. Economic fundamentals have not changed and the market will stabilise at any moment.\"</p>\n<p>Other major securities dailies echoed the commentary in market reports.</p>\n<p>In a front page story citing domestic fund managers, the official China Securities Journal said the sell-off was a \"structural adjustment\", a sustained plunge is unlikely and the market does not face systemic risk.</p>\n<p>A story in the state-run Shanghai Securities News quoted domestic analysts as saying that the sell-off would not continue, and that the market will gradually stabilise.</p>\n<p>\"For institutions, the decline brings the opportunity for positioning in high-quality shares,\" it said.</p>\n<p>What started off as a sell-off in shares on Monday had spread into fixed income and foreign exchange markets by Tuesday afternoon, sending the yuan falling through psychologically significant levels and pushing Chinese sovereign bond yields, and the cost of insurance against a default in China's dollar debt, higher.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China state-owned daily urges calm after market rout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina state-owned daily urges calm after market rout\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-28 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday after investors dumped mainland shares for a second day on worries over the impact of tighter government regulations.</p>\n<p>Regulatory moves aimed at the education, property and technology sectors sparked heavy selling this week in Chinese markets, and have left global investors bruised and uncertain over the outlook for investments in Chinese firms.</p>\n<p>In a front page commentary on Wednesday, the state-owned Securities Times said that systemic risks \"do not exist in the A-share market overall.\"</p>\n<p>\"The macroeconomy is still in a steady rebound stage, and short-term fluctuations do not change the long-term positive outlook for A-shares,\" the commentary said.</p>\n<p>\"The recent market decline to some extent reflects misinterpretation of policies and a venting of emotion. Economic fundamentals have not changed and the market will stabilise at any moment.\"</p>\n<p>Other major securities dailies echoed the commentary in market reports.</p>\n<p>In a front page story citing domestic fund managers, the official China Securities Journal said the sell-off was a \"structural adjustment\", a sustained plunge is unlikely and the market does not face systemic risk.</p>\n<p>A story in the state-run Shanghai Securities News quoted domestic analysts as saying that the sell-off would not continue, and that the market will gradually stabilise.</p>\n<p>\"For institutions, the decline brings the opportunity for positioning in high-quality shares,\" it said.</p>\n<p>What started off as a sell-off in shares on Monday had spread into fixed income and foreign exchange markets by Tuesday afternoon, sending the yuan falling through psychologically significant levels and pushing Chinese sovereign bond yields, and the cost of insurance against a default in China's dollar debt, higher.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAAS":"中汽系统"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154943718","content_text":"SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday after investors dumped mainland shares for a second day on worries over the impact of tighter government regulations.\nRegulatory moves aimed at the education, property and technology sectors sparked heavy selling this week in Chinese markets, and have left global investors bruised and uncertain over the outlook for investments in Chinese firms.\nIn a front page commentary on Wednesday, the state-owned Securities Times said that systemic risks \"do not exist in the A-share market overall.\"\n\"The macroeconomy is still in a steady rebound stage, and short-term fluctuations do not change the long-term positive outlook for A-shares,\" the commentary said.\n\"The recent market decline to some extent reflects misinterpretation of policies and a venting of emotion. Economic fundamentals have not changed and the market will stabilise at any moment.\"\nOther major securities dailies echoed the commentary in market reports.\nIn a front page story citing domestic fund managers, the official China Securities Journal said the sell-off was a \"structural adjustment\", a sustained plunge is unlikely and the market does not face systemic risk.\nA story in the state-run Shanghai Securities News quoted domestic analysts as saying that the sell-off would not continue, and that the market will gradually stabilise.\n\"For institutions, the decline brings the opportunity for positioning in high-quality shares,\" it said.\nWhat started off as a sell-off in shares on Monday had spread into fixed income and foreign exchange markets by Tuesday afternoon, sending the yuan falling through psychologically significant levels and pushing Chinese sovereign bond yields, and the cost of insurance against a default in China's dollar debt, higher.","news_type":1,"symbols_score_info":{"CAAS":0.9}},"isVote":1,"tweetType":1,"viewCount":754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803212015,"gmtCreate":1627441017037,"gmtModify":1703490026681,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803212015","repostId":"2154991792","repostType":4,"repost":{"id":"2154991792","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627428087,"share":"https://ttm.financial/m/news/2154991792?lang=en_US&edition=fundamental","pubTime":"2021-07-28 07:21","market":"us","language":"en","title":"Wall St snaps five-day up streak as caution rises before tech earnings, Fed","url":"https://stock-news.laohu8.com/highlight/detail?id=2154991792","media":"Reuters","summary":"NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the t","content":"<p>NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the three major indexes, as investors were cautious before results from top tech and internet names and Wednesday's Federal Reserve announcement.</p>\n<p>The Nasdaq led the day's declines, registering its biggest daily percentage drop since May 12, but the three indexes pared losses heading into the close and ended well off the lows of the session.</p>\n<p>Shares of Apple Inc, Microsoft Corp&nbsp;and Google parent Alphabet Inc , which all reported earnings after the bell, dropped and weighed the most on the Nasdaq and S&amp;P 500 along with Amazon.com Inc , which is expected to report results later this week.</p>\n<p>Also, electric-car maker Tesla Inc fell 2%, a day after it posted a bigger-than-expected second-quarter profit but said a global chip shortage that led to temporary factory shutdowns for the automaker remains serious.</p>\n<p>Shares of the heavily weighted tech and internet companies have run up recently and last week regained leadership in the market, putting their results even more in the spotlight.</p>\n<p>\"Expectations are so high. They're going to have good numbers ... but we are expecting much more or maybe they will talk down the second half of the year,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago.</p>\n<p>Adding to the cautious tone is the outlook for U.S.-listed Chinese stocks, he said. The shares including Baidu extended losses as fears over more regulations in the mainland persisted.</p>\n<p>\"There's a fair amount of (U.S.) investors in those companies,\" Nolte said.</p>\n<p>Uncertainty also rose as the Fed began its two-day meeting, with investors looking for signs on when it intends to begin reining in its massive stimulus program.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 85.79 points, or 0.24%, to 35,058.52, the S&amp;P 500&nbsp;lost 20.84 points, or 0.47%, to 4,401.46 and the Nasdaq Composite &nbsp;dropped 180.14 points, or 1.21%, to 14,660.58.</p>\n<p>Helping to support the Dow, shares of McDonald's Corp&nbsp;rose 1% ahead of its results due before the bell on Wednesday.</p>\n<p>In another sign that investors were in a risk-off mood, defensive sectors such as real estate&nbsp;and utilities&nbsp;were the two best-performing S&amp;P 500 categories for the day, and U.S. Treasuries prices rose.</p>\n<p>Intel Corp&nbsp;shares dropped 2.1% after it said its factories would start building Qualcomm chips and laid out a road map to expand its new foundry business.</p>\n<p>Volume on U.S. exchanges was 10.36 billion shares, compared with the 9.86 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.87-to-1 ratio; on Nasdaq, a 2.65-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 44 new 52-week highs and no new lows; the Nasdaq Composite recorded 39 new highs and 235 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St snaps five-day up streak as caution rises before tech earnings, Fed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St snaps five-day up streak as caution rises before tech earnings, Fed\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-28 07:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the three major indexes, as investors were cautious before results from top tech and internet names and Wednesday's Federal Reserve announcement.</p>\n<p>The Nasdaq led the day's declines, registering its biggest daily percentage drop since May 12, but the three indexes pared losses heading into the close and ended well off the lows of the session.</p>\n<p>Shares of Apple Inc, Microsoft Corp&nbsp;and Google parent Alphabet Inc , which all reported earnings after the bell, dropped and weighed the most on the Nasdaq and S&amp;P 500 along with Amazon.com Inc , which is expected to report results later this week.</p>\n<p>Also, electric-car maker Tesla Inc fell 2%, a day after it posted a bigger-than-expected second-quarter profit but said a global chip shortage that led to temporary factory shutdowns for the automaker remains serious.</p>\n<p>Shares of the heavily weighted tech and internet companies have run up recently and last week regained leadership in the market, putting their results even more in the spotlight.</p>\n<p>\"Expectations are so high. They're going to have good numbers ... but we are expecting much more or maybe they will talk down the second half of the year,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago.</p>\n<p>Adding to the cautious tone is the outlook for U.S.-listed Chinese stocks, he said. The shares including Baidu extended losses as fears over more regulations in the mainland persisted.</p>\n<p>\"There's a fair amount of (U.S.) investors in those companies,\" Nolte said.</p>\n<p>Uncertainty also rose as the Fed began its two-day meeting, with investors looking for signs on when it intends to begin reining in its massive stimulus program.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 85.79 points, or 0.24%, to 35,058.52, the S&amp;P 500&nbsp;lost 20.84 points, or 0.47%, to 4,401.46 and the Nasdaq Composite &nbsp;dropped 180.14 points, or 1.21%, to 14,660.58.</p>\n<p>Helping to support the Dow, shares of McDonald's Corp&nbsp;rose 1% ahead of its results due before the bell on Wednesday.</p>\n<p>In another sign that investors were in a risk-off mood, defensive sectors such as real estate&nbsp;and utilities&nbsp;were the two best-performing S&amp;P 500 categories for the day, and U.S. Treasuries prices rose.</p>\n<p>Intel Corp&nbsp;shares dropped 2.1% after it said its factories would start building Qualcomm chips and laid out a road map to expand its new foundry business.</p>\n<p>Volume on U.S. exchanges was 10.36 billion shares, compared with the 9.86 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.87-to-1 ratio; on Nasdaq, a 2.65-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 44 new 52-week highs and no new lows; the Nasdaq Composite recorded 39 new highs and 235 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154991792","content_text":"NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the three major indexes, as investors were cautious before results from top tech and internet names and Wednesday's Federal Reserve announcement.\nThe Nasdaq led the day's declines, registering its biggest daily percentage drop since May 12, but the three indexes pared losses heading into the close and ended well off the lows of the session.\nShares of Apple Inc, Microsoft Corp and Google parent Alphabet Inc , which all reported earnings after the bell, dropped and weighed the most on the Nasdaq and S&P 500 along with Amazon.com Inc , which is expected to report results later this week.\nAlso, electric-car maker Tesla Inc fell 2%, a day after it posted a bigger-than-expected second-quarter profit but said a global chip shortage that led to temporary factory shutdowns for the automaker remains serious.\nShares of the heavily weighted tech and internet companies have run up recently and last week regained leadership in the market, putting their results even more in the spotlight.\n\"Expectations are so high. They're going to have good numbers ... but we are expecting much more or maybe they will talk down the second half of the year,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago.\nAdding to the cautious tone is the outlook for U.S.-listed Chinese stocks, he said. The shares including Baidu extended losses as fears over more regulations in the mainland persisted.\n\"There's a fair amount of (U.S.) investors in those companies,\" Nolte said.\nUncertainty also rose as the Fed began its two-day meeting, with investors looking for signs on when it intends to begin reining in its massive stimulus program.\nThe Dow Jones Industrial Average fell 85.79 points, or 0.24%, to 35,058.52, the S&P 500 lost 20.84 points, or 0.47%, to 4,401.46 and the Nasdaq Composite  dropped 180.14 points, or 1.21%, to 14,660.58.\nHelping to support the Dow, shares of McDonald's Corp rose 1% ahead of its results due before the bell on Wednesday.\nIn another sign that investors were in a risk-off mood, defensive sectors such as real estate and utilities were the two best-performing S&P 500 categories for the day, and U.S. Treasuries prices rose.\nIntel Corp shares dropped 2.1% after it said its factories would start building Qualcomm chips and laid out a road map to expand its new foundry business.\nVolume on U.S. exchanges was 10.36 billion shares, compared with the 9.86 billion average for the full session over the last 20 trading days.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.87-to-1 ratio; on Nasdaq, a 2.65-to-1 ratio favored decliners.\nThe S&P 500 posted 44 new 52-week highs and no new lows; the Nasdaq Composite recorded 39 new highs and 235 new lows.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809574634,"gmtCreate":1627383596328,"gmtModify":1703488826605,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"*claps*","listText":"*claps*","text":"*claps*","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809574634","repostId":"2154972069","repostType":2,"repost":{"id":"2154972069","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627382460,"share":"https://ttm.financial/m/news/2154972069?lang=en_US&edition=fundamental","pubTime":"2021-07-27 18:41","market":"hk","language":"en","title":"GE stock surges after profit and revenue beats, a surprise swing to positive free cash flow","url":"https://stock-news.laohu8.com/highlight/detail?id=2154972069","media":"Dow Jones","summary":"MW GE stock surges after profit and revenue beats, a surprise swing to positive free cash flow\n\n\n  S","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW GE stock surges after profit and revenue beats, a surprise swing to positive free cash flow\n</p>\n<p>\n  Shares of General Electric Co. <a href=\"https://laohu8.com/S/GE\">$(GE)$</a> shot up 4.0% in premarket trading Tuesday, after the industrial conglomerate reported second-quarter profit and revenue that beat expectations, and surprisingly generated positive free cash flow. On a net basis, the loss per shares narrowed to 14 cents from 26 cents, while excluding nonrecurring items, GE swung to adjusted earnings per share of 5 cents from a loss of 14 cents to beat the FactSet EPS consensus of 3 cents. Revenue rose 9% to $18.28 billion, above the FactSet consensus of $18.14 billion. Industrial free cash flow was about positive $400 million, compared with the FactSet consensus of negative $338.3 million, and the company raised the 2021 FCF guidance range to $3.5 billion to $5.0 billion from $2.5 billion to $4.5 billion. Among GE's business segments, revenue for Aviation rose 10% to $4.84 billion, but was below the FactSet consensus of $5.16 billion; Healthcare revenue grew 14% to $4.85 billion, well above expectations of $4.30 billion; Power revenue rose 3% to $4.30 billion to top versus expectations of $4.09 billion and Renewable Energy revenue jumped 16% to $4.05 billion to exceed expectations of $3.87 billion. \"Momentum is building across our businesses, driven by Healthcare and services overall, with Aviation showing early signs of recovery,\" said Chief Executive Lawrence Culp. GE's stock has run up 19.6% year to date through Monday, while the SPDR Industrial Select Sector ETF <a href=\"https://laohu8.com/S/XLI\">$(XLI)$</a> has gained 17.0% and the S&amp;P 500  has advanced 17.7%. \n</p>\n<p>\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  July 27, 2021 06:41 ET (10:41 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GE stock surges after profit and revenue beats, a surprise swing to positive free cash flow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGE stock surges after profit and revenue beats, a surprise swing to positive free cash flow\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-27 18:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW GE stock surges after profit and revenue beats, a surprise swing to positive free cash flow\n</p>\n<p>\n  Shares of General Electric Co. <a href=\"https://laohu8.com/S/GE\">$(GE)$</a> shot up 4.0% in premarket trading Tuesday, after the industrial conglomerate reported second-quarter profit and revenue that beat expectations, and surprisingly generated positive free cash flow. On a net basis, the loss per shares narrowed to 14 cents from 26 cents, while excluding nonrecurring items, GE swung to adjusted earnings per share of 5 cents from a loss of 14 cents to beat the FactSet EPS consensus of 3 cents. Revenue rose 9% to $18.28 billion, above the FactSet consensus of $18.14 billion. Industrial free cash flow was about positive $400 million, compared with the FactSet consensus of negative $338.3 million, and the company raised the 2021 FCF guidance range to $3.5 billion to $5.0 billion from $2.5 billion to $4.5 billion. Among GE's business segments, revenue for Aviation rose 10% to $4.84 billion, but was below the FactSet consensus of $5.16 billion; Healthcare revenue grew 14% to $4.85 billion, well above expectations of $4.30 billion; Power revenue rose 3% to $4.30 billion to top versus expectations of $4.09 billion and Renewable Energy revenue jumped 16% to $4.05 billion to exceed expectations of $3.87 billion. \"Momentum is building across our businesses, driven by Healthcare and services overall, with Aviation showing early signs of recovery,\" said Chief Executive Lawrence Culp. GE's stock has run up 19.6% year to date through Monday, while the SPDR Industrial Select Sector ETF <a href=\"https://laohu8.com/S/XLI\">$(XLI)$</a> has gained 17.0% and the S&amp;P 500  has advanced 17.7%. \n</p>\n<p>\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  July 27, 2021 06:41 ET (10:41 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GE":"GE航空航天","XLI":"工业指数ETF-SPDR"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154972069","content_text":"MW GE stock surges after profit and revenue beats, a surprise swing to positive free cash flow\n\n\n  Shares of General Electric Co. $(GE)$ shot up 4.0% in premarket trading Tuesday, after the industrial conglomerate reported second-quarter profit and revenue that beat expectations, and surprisingly generated positive free cash flow. On a net basis, the loss per shares narrowed to 14 cents from 26 cents, while excluding nonrecurring items, GE swung to adjusted earnings per share of 5 cents from a loss of 14 cents to beat the FactSet EPS consensus of 3 cents. Revenue rose 9% to $18.28 billion, above the FactSet consensus of $18.14 billion. Industrial free cash flow was about positive $400 million, compared with the FactSet consensus of negative $338.3 million, and the company raised the 2021 FCF guidance range to $3.5 billion to $5.0 billion from $2.5 billion to $4.5 billion. Among GE's business segments, revenue for Aviation rose 10% to $4.84 billion, but was below the FactSet consensus of $5.16 billion; Healthcare revenue grew 14% to $4.85 billion, well above expectations of $4.30 billion; Power revenue rose 3% to $4.30 billion to top versus expectations of $4.09 billion and Renewable Energy revenue jumped 16% to $4.05 billion to exceed expectations of $3.87 billion. \"Momentum is building across our businesses, driven by Healthcare and services overall, with Aviation showing early signs of recovery,\" said Chief Executive Lawrence Culp. GE's stock has run up 19.6% year to date through Monday, while the SPDR Industrial Select Sector ETF $(XLI)$ has gained 17.0% and the S&P 500  has advanced 17.7%. \n\n\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  July 27, 2021 06:41 ET (10:41 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"XLI":0.9,"GE":0.9}},"isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809592134,"gmtCreate":1627376795928,"gmtModify":1703488707453,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Latest&nbsp;","listText":"Latest&nbsp;","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/809592134","repostId":"1154449552","repostType":4,"isVote":1,"tweetType":1,"viewCount":644,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809598459,"gmtCreate":1627376716471,"gmtModify":1703488705348,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Sigh","listText":"Sigh","text":"Sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809598459","repostId":"2154813991","repostType":4,"repost":{"id":"2154813991","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627371927,"share":"https://ttm.financial/m/news/2154813991?lang=en_US&edition=fundamental","pubTime":"2021-07-27 15:45","market":"sh","language":"en","title":"China shares plunge to 8-month low on regulatory woes","url":"https://stock-news.laohu8.com/highlight/detail?id=2154813991","media":"Reuters","summary":"* Property, tech, education hit by regulatory tightening fears. SHANGHAI, July 27  - Chinese A-shares and Hong Kong's benchmark index extended heavy losses to hit multi-month closing lows on Tuesday, as investors worried over the impact of tighter government regulations, while a surge in COVID-19 cases dealt a further blow to sentiment.China's blue-chip CSI300 index ended down 3.53% at its lowest close since November, extending Monday's 3.2% selloff. Losses spanned the financial, consumer staple","content":"<p>* China, Hong Kong stocks extend steep selloff</p>\n<p>* Property, tech, education hit by regulatory tightening fears</p>\n<p>* Delta variant behind cluster in city of Nanjing</p>\n<p>SHANGHAI, July 27 (Reuters) - Chinese A-shares and Hong Kong's benchmark index extended heavy losses to hit multi-month closing lows on Tuesday, as investors worried over the impact of tighter government regulations, while a surge in COVID-19 cases dealt a further blow to sentiment.</p>\n<p>China's blue-chip CSI300 index ended down 3.53% at its lowest close since November, extending Monday's 3.2% selloff. Losses spanned the financial, consumer staples and real estate sectors.</p>\n<p>The Shanghai Composite index gave up early gains to end 2.49% lower at 3,381.18, its lowest close since March 25.</p>\n<p>Falls were wide-ranging, with the CSI financial sector sub-index down 3.17%, the consumer staples sector&nbsp;off 4.75% and the healthcare sub-index down 3.9%.</p>\n<p>In late trade in Hong Kong, the benchmark Hang Seng Index&nbsp;was down as much as 5.46% after a 4.1% drop in the previous session, and the Hang Seng China Enterprises Index&nbsp;plunged as much as 6.78%.</p>\n<p>The Hang Seng Tech index crashed through its previous record low, falling more than 9%.</p>\n<p>The rout came after a shakeout on Monday spurred by new rules reining in China's $120 billion private tutoring sector, sending some shares crashing more than 45%, and new regulatory moves targeting technology and property.</p>\n<p>\"Beijing's severe crackdown on the tech and education sectors had ignited the re-pricing of significant regulation risks on investment for Chinese private companies,\" Ken Cheung, chief Asian FX strategist at Mizuhuo Bank, said in a note.</p>\n<p>\"As such, foreign investors will request a deeper discount on such Chinese investment or even cut the exposure on Chinese companies,\" Cheung added.</p>\n<p>Education shares continued to slide on Tuesday, with New Oriental Education &amp; Technology Group Co falling 7.25%, taking its drop over the last three sessions to more than 70%, while the CSI education index tumbled 5.18%.</p>\n<p><b>WORST-CASE SCENARIO</b></p>\n<p>Anita Chu, an analyst at CCB International, said in a research report the unfavourable regulatory environment had left little room for a business turnaround, and issued a downgrade and reduced target price for New Oriental.</p>\n<p>\"If the final version of the policy comes to resemble its current form, we envision a worst-case scenario whereby existing listed-AST (after-school tutoring) operators will be compelled to spin off their K9 AST operations from the listco, or else de-list by way of privatisation,\" Chu said.</p>\n<p>\"According to our estimates, the potential spinoff of K9 AST operations would take 60-70% off the earnings of New Oriental and 80-90% off (New York-listed) TAL Education.\"</p>\n<p>In Hong Kong, heavily indebted developer <a href=\"https://laohu8.com/S/EGRNF\">China Evergrande Group</a> extended its losses, spiralling more than 16% lower to 4-1/2 year lows, after the company said it would cancel a special dividend proposal.</p>\n<p>The broader property sector in Hong Kong sank 3.6% and real estate A-shares ended 4.51% lower.</p>\n<p>Adding to broader concerns about the economic outlook, profit growth at China's industrial firms slowed for a fourth straight month in June, as high raw material prices weighed on factories' margins.</p>\n<p>A surge in highly contagious Delta variant COVID-19 cases centred on the eastern city of Nanjing also spurred concern on Tuesday.</p>\n<p>But Zhiwei Zhang, chief economist at Pinpoint Asset Management, said broader economic concerns were contained for now.</p>\n<p>\"The market correction seems to reflect some investors' concern about government's policy stance on the capital market. We don't think investors are concerned about the economy at this stage,\" he said in an emailed comment.</p>\n<p>But pointing to rising concern late on Tuesday, China's yuan&nbsp;turned around sharply from small gains against the dollar to weaken past the 6.5 per dollar level. It was last quoted at 6.5103 per dollar, 0.43% weaker on the day.</p>\n<p>The offshore yuan also whipsawed lower, blasting through the 6.5 level to a low of 6.5225 per dollar, down more than 0.6% from a day earlier.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China shares plunge to 8-month low on regulatory woes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina shares plunge to 8-month low on regulatory woes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-27 15:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* China, Hong Kong stocks extend steep selloff</p>\n<p>* Property, tech, education hit by regulatory tightening fears</p>\n<p>* Delta variant behind cluster in city of Nanjing</p>\n<p>SHANGHAI, July 27 (Reuters) - Chinese A-shares and Hong Kong's benchmark index extended heavy losses to hit multi-month closing lows on Tuesday, as investors worried over the impact of tighter government regulations, while a surge in COVID-19 cases dealt a further blow to sentiment.</p>\n<p>China's blue-chip CSI300 index ended down 3.53% at its lowest close since November, extending Monday's 3.2% selloff. Losses spanned the financial, consumer staples and real estate sectors.</p>\n<p>The Shanghai Composite index gave up early gains to end 2.49% lower at 3,381.18, its lowest close since March 25.</p>\n<p>Falls were wide-ranging, with the CSI financial sector sub-index down 3.17%, the consumer staples sector&nbsp;off 4.75% and the healthcare sub-index down 3.9%.</p>\n<p>In late trade in Hong Kong, the benchmark Hang Seng Index&nbsp;was down as much as 5.46% after a 4.1% drop in the previous session, and the Hang Seng China Enterprises Index&nbsp;plunged as much as 6.78%.</p>\n<p>The Hang Seng Tech index crashed through its previous record low, falling more than 9%.</p>\n<p>The rout came after a shakeout on Monday spurred by new rules reining in China's $120 billion private tutoring sector, sending some shares crashing more than 45%, and new regulatory moves targeting technology and property.</p>\n<p>\"Beijing's severe crackdown on the tech and education sectors had ignited the re-pricing of significant regulation risks on investment for Chinese private companies,\" Ken Cheung, chief Asian FX strategist at Mizuhuo Bank, said in a note.</p>\n<p>\"As such, foreign investors will request a deeper discount on such Chinese investment or even cut the exposure on Chinese companies,\" Cheung added.</p>\n<p>Education shares continued to slide on Tuesday, with New Oriental Education &amp; Technology Group Co falling 7.25%, taking its drop over the last three sessions to more than 70%, while the CSI education index tumbled 5.18%.</p>\n<p><b>WORST-CASE SCENARIO</b></p>\n<p>Anita Chu, an analyst at CCB International, said in a research report the unfavourable regulatory environment had left little room for a business turnaround, and issued a downgrade and reduced target price for New Oriental.</p>\n<p>\"If the final version of the policy comes to resemble its current form, we envision a worst-case scenario whereby existing listed-AST (after-school tutoring) operators will be compelled to spin off their K9 AST operations from the listco, or else de-list by way of privatisation,\" Chu said.</p>\n<p>\"According to our estimates, the potential spinoff of K9 AST operations would take 60-70% off the earnings of New Oriental and 80-90% off (New York-listed) TAL Education.\"</p>\n<p>In Hong Kong, heavily indebted developer <a href=\"https://laohu8.com/S/EGRNF\">China Evergrande Group</a> extended its losses, spiralling more than 16% lower to 4-1/2 year lows, after the company said it would cancel a special dividend proposal.</p>\n<p>The broader property sector in Hong Kong sank 3.6% and real estate A-shares ended 4.51% lower.</p>\n<p>Adding to broader concerns about the economic outlook, profit growth at China's industrial firms slowed for a fourth straight month in June, as high raw material prices weighed on factories' margins.</p>\n<p>A surge in highly contagious Delta variant COVID-19 cases centred on the eastern city of Nanjing also spurred concern on Tuesday.</p>\n<p>But Zhiwei Zhang, chief economist at Pinpoint Asset Management, said broader economic concerns were contained for now.</p>\n<p>\"The market correction seems to reflect some investors' concern about government's policy stance on the capital market. We don't think investors are concerned about the economy at this stage,\" he said in an emailed comment.</p>\n<p>But pointing to rising concern late on Tuesday, China's yuan&nbsp;turned around sharply from small gains against the dollar to weaken past the 6.5 per dollar level. It was last quoted at 6.5103 per dollar, 0.43% weaker on the day.</p>\n<p>The offshore yuan also whipsawed lower, blasting through the 6.5 level to a low of 6.5225 per dollar, down more than 0.6% from a day earlier.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"399001":"深证成指","399006":"创业板指","000001.SH":"上证指数","HSI":"恒生指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154813991","content_text":"* China, Hong Kong stocks extend steep selloff\n* Property, tech, education hit by regulatory tightening fears\n* Delta variant behind cluster in city of Nanjing\nSHANGHAI, July 27 (Reuters) - Chinese A-shares and Hong Kong's benchmark index extended heavy losses to hit multi-month closing lows on Tuesday, as investors worried over the impact of tighter government regulations, while a surge in COVID-19 cases dealt a further blow to sentiment.\nChina's blue-chip CSI300 index ended down 3.53% at its lowest close since November, extending Monday's 3.2% selloff. Losses spanned the financial, consumer staples and real estate sectors.\nThe Shanghai Composite index gave up early gains to end 2.49% lower at 3,381.18, its lowest close since March 25.\nFalls were wide-ranging, with the CSI financial sector sub-index down 3.17%, the consumer staples sector off 4.75% and the healthcare sub-index down 3.9%.\nIn late trade in Hong Kong, the benchmark Hang Seng Index was down as much as 5.46% after a 4.1% drop in the previous session, and the Hang Seng China Enterprises Index plunged as much as 6.78%.\nThe Hang Seng Tech index crashed through its previous record low, falling more than 9%.\nThe rout came after a shakeout on Monday spurred by new rules reining in China's $120 billion private tutoring sector, sending some shares crashing more than 45%, and new regulatory moves targeting technology and property.\n\"Beijing's severe crackdown on the tech and education sectors had ignited the re-pricing of significant regulation risks on investment for Chinese private companies,\" Ken Cheung, chief Asian FX strategist at Mizuhuo Bank, said in a note.\n\"As such, foreign investors will request a deeper discount on such Chinese investment or even cut the exposure on Chinese companies,\" Cheung added.\nEducation shares continued to slide on Tuesday, with New Oriental Education & Technology Group Co falling 7.25%, taking its drop over the last three sessions to more than 70%, while the CSI education index tumbled 5.18%.\nWORST-CASE SCENARIO\nAnita Chu, an analyst at CCB International, said in a research report the unfavourable regulatory environment had left little room for a business turnaround, and issued a downgrade and reduced target price for New Oriental.\n\"If the final version of the policy comes to resemble its current form, we envision a worst-case scenario whereby existing listed-AST (after-school tutoring) operators will be compelled to spin off their K9 AST operations from the listco, or else de-list by way of privatisation,\" Chu said.\n\"According to our estimates, the potential spinoff of K9 AST operations would take 60-70% off the earnings of New Oriental and 80-90% off (New York-listed) TAL Education.\"\nIn Hong Kong, heavily indebted developer China Evergrande Group extended its losses, spiralling more than 16% lower to 4-1/2 year lows, after the company said it would cancel a special dividend proposal.\nThe broader property sector in Hong Kong sank 3.6% and real estate A-shares ended 4.51% lower.\nAdding to broader concerns about the economic outlook, profit growth at China's industrial firms slowed for a fourth straight month in June, as high raw material prices weighed on factories' margins.\nA surge in highly contagious Delta variant COVID-19 cases centred on the eastern city of Nanjing also spurred concern on Tuesday.\nBut Zhiwei Zhang, chief economist at Pinpoint Asset Management, said broader economic concerns were contained for now.\n\"The market correction seems to reflect some investors' concern about government's policy stance on the capital market. We don't think investors are concerned about the economy at this stage,\" he said in an emailed comment.\nBut pointing to rising concern late on Tuesday, China's yuan turned around sharply from small gains against the dollar to weaken past the 6.5 per dollar level. It was last quoted at 6.5103 per dollar, 0.43% weaker on the day.\nThe offshore yuan also whipsawed lower, blasting through the 6.5 level to a low of 6.5225 per dollar, down more than 0.6% from a day earlier.","news_type":1,"symbols_score_info":{"399001":0.9,"399006":0.9,"000001.SH":0.9,"HSI":0.9}},"isVote":1,"tweetType":1,"viewCount":885,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809598340,"gmtCreate":1627376656580,"gmtModify":1703488705185,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809598340","repostId":"1154159969","repostType":4,"repost":{"id":"1154159969","kind":"news","pubTimestamp":1627372017,"share":"https://ttm.financial/m/news/1154159969?lang=en_US&edition=fundamental","pubTime":"2021-07-27 15:46","market":"us","language":"en","title":"Netflix: Calculating Its Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=1154159969","media":"seekingalpha","summary":"Summary\n\nOur forecasts are based purely on fundamentals.\nWe expect Netflix to see margin expansion g","content":"<p>Summary</p>\n<ul>\n <li>Our forecasts are based purely on fundamentals.</li>\n <li>We expect Netflix to see margin expansion going forward.</li>\n <li>Netflix is undervalued under current market conditions.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a06802a1c9fe18b04bc7c3eae704b91\" tg-width=\"1536\" tg-height=\"1022\" width=\"100%\" height=\"auto\"><span>Pascal Le Segretain/Getty Images News</span></p>\n<p>Netflix Inc (NFLX) has the potential to perform well. However, we highlight what you need to consider before jumping into the stock. We base our forecast purely on the company's fundamentals. By doing so, we are able to point to the specific growth drivers rooted in numbers as opposed to perceived potential. In addition, we believe that Netflix's margins will expand going forward. Using the fundamentals allows us to more reasonably estimate the company's margin expansion.</p>\n<p><b>Valuation</b></p>\n<p>Forecasting is not easy and it's difficult to be precise. However, the point of forecasting is not to be right but to be reasonable. Our projections are based on the company's fundamentals. We try to determine what growth rates the company can fundamentally sustain up until 2025.</p>\n<p>We will begin with the growth rate we expect for fiscal year 2021. The first thing we need is to determine what will constitute as reinvestment. For Netflix, it will be research and development, marketing, capital expenditures, net investment in content, and change in net working capital.</p>\n<p>Please note that we measure net investment in content as the cash spent on developing content subtracted by the amortization of previously developed content. Our assumption is that the amortized amount is the \"maintenance content\" needed to maintain the interest of current users and doesn't contribute to growth. The net investment in content is what we consider the \"growth content\" that contributes to attracting new users or justifying price increases.</p>\n<p>In addition, that depreciation and amortization expense is subtracted from the reinvestment rate as it is used as a proxy for maintenance capex that does not contribute to growth.</p>\n<p>The next step is to find the revenue-to-capital ratio. This measures how much revenue a company generates for each dollar in capital. Once we have both numbers, we multiply them to calculate the fundamental growth rate.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f1190d7305518113889190a4e5d4e177\" tg-width=\"354\" tg-height=\"462\" width=\"100%\" height=\"auto\"><span>Source: Author</span></p>\n<p>In the picture above, we see that the reinvestment rate was 21.44% of revenue and revenue to capital was 93.39%. Therefore, the fundamental growth rate for fiscal year 2021 equals 20.02%. This is slightly above analysts' expectations but by very little.</p>\n<p>The next step is to determine the degree of operating leverage, which is a multiple that measures how much the operating income of a company will change in response to a change in sales. Netflix has had a ratio of over 2 over the past several years. To be conservative, we will use 2 and reduce it each year. In addition, we did the same thing with gross margins using a starting point of 1.08.</p>\n<p>As the EBIT margin increases, the reinvestment rate decreases because R&amp;D and marketing expenses become a smaller percentage of revenue, resulting in a slowdown of growth. We measure this slowdown by setting R&amp;D and marketing to 70% of total operating expenses (percentage in fiscal year 2020). We then calculate the future fundamental growth rates with the projected numbers as follows:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8251e55395490f4c6d6347fef3a9a08f\" tg-width=\"640\" tg-height=\"605\" width=\"100%\" height=\"auto\"><span>Source: Author</span></p>\n<p>We used the average capital expenditure and D&amp;A margins of the last three years. Now we will input these numbers into a DCF using the company's weighted average cost of capital of 5% based on&nbsp;<b>current market conditions.</b>Please note that we grouped net content investment with capital expenditures.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cfb2441365f739f8ec307436cfd81926\" tg-width=\"640\" tg-height=\"259\" width=\"100%\" height=\"auto\"><span>Source: Author using Finbox tools</span></p>\n<p>As you can see, with a 5% discount rate, 21% tax rate, 2% terminal growth rate, and a forecast based on fundamentals, the company has the potential for 24.6% upside. Of course, discount rates are always changing and not everyone likes to use current discount rates. Therefore, we made the chart below to demonstrate the fair value at each discount rate and terminal growth rate:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e8a824dfed49d58dacb3f22cad000213\" tg-width=\"430\" tg-height=\"209\" width=\"100%\" height=\"auto\"><span>Source: Author</span></p>\n<p>As you can see, if interest rates stay low for an extended period of time, Netflix can potentially see solid upside. However, there isn't much room for changes in the discount rates, and therefore should be careful if you believe discount rates are going up.</p>\n<p><b>Checking for Consistencies in the Forecast</b></p>\n<p>Let's make sure everything makes sense in the forecast. We'll begin with revenue growth. You can see that we expect revenue growth to accelerate in 2022 before gradually decreasing in the following years. This is because we expect Netflix to increase its net content investment in 2021. The company has stated that it willincrease overall investment in contentto $17 billion, up from $11.8 billion in 2020. This consequently leads to a higher reinvestment rate and the potential to accelerate revenue growth. This seems reasonable to us because it has happened to Netflix in the past where revenue growth has accelerated.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4008559ff06f06414badc2e9f7509765\" tg-width=\"640\" tg-height=\"71\" width=\"100%\" height=\"auto\"><span>Source: Author</span></p>\n<p>In addition, the net content investment in our forecast is similar to the absolute amounts Netflix spent pre-pandemic.</p>\n<p>Furthermore, management expects free cash flow for this year to be break even or slightly higher. It's hard to say what slightly above means for the management team. Although $119 million is exactly slightly above breakeven, it is still significantly less than what it was in 2020. However, management hasn't specified whether it is unlevered or levered free cash flow and it is possible that unlevered free cash flow (which is what we used) might be higher. It is also possible that Netflix might have a stronger than expected second half. Regardless, the $119 million is immaterial to the valuation overall.</p>\n<p><b>Growth Catalysts</b></p>\n<p>An obvious growth catalyst that impacts our forecast is the company's increase in content spend. Content is the most important factor when it comes to entertainment-based businesses. Netflix can have the most technologically advanced platform in the world but, if the content is boring, then nobody would use it.</p>\n<p>In addition, although streaming has become increasingly popular, cable still accounts for the largest share of total tv time in the US:</p>\n<p><img src=\"https://static.tigerbbs.com/fa87184a65693ead5a02993493df64f9\" tg-width=\"640\" tg-height=\"434\" width=\"100%\" height=\"auto\"></p>\n<p>As you can see, the streaming market as a whole is only 27% of the total share. Despite all the talk about increasing competition, there is still plenty of room for the streaming segment to grow as a whole. Therefore, even if Netflix loses market share to other streamers, it will still be able to grow in absolute terms.</p>\n<p>Finally, Netflix's venture intovideo gamescould be beneficial if executed correctly. However, we don't have too much conviction in this idea just yet, which we talk more about in the \"risks\" section below.</p>\n<p><b>Risks</b></p>\n<p>We will begin with video games. The video game industry is very tough. With all the money that Amazon.com Inc (AMZN) generates, it hasstruggled to releasea successful game since starting the division in 2014. Likewise, Alphabet Inc (GOOG) has suffered asimilar problem. This implies that developing successful video games is not as easy as throwing money at developers and requires a certain level of specialization.</p>\n<p>Speaking of throwing money, Netflix's increased spend on content may not yield positive results if it is rushed. Thisarticledemonstrates that people can notice when projects are rushed. Although the article is from 2019, it is an important reminder that the quality of the content is likely to be more important than the quantity. If Netflix fails to deliver on quality, it could see subscriber counts drop.</p>\n<p><b>Final Thoughts</b></p>\n<p>Netflix is undervalued under current market conditions; however, it doesn't provide enough of a margin of safety if the interest/discount rates increase. Thus, although Netflix may continue to do well, we will stay on the sidelines for now.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix: Calculating Its Intrinsic Value</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix: Calculating Its Intrinsic Value\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 15:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4441533-netflix-calculating-its-intrinsic-value><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nOur forecasts are based purely on fundamentals.\nWe expect Netflix to see margin expansion going forward.\nNetflix is undervalued under current market conditions.\n\nPascal Le Segretain/Getty ...</p>\n\n<a href=\"https://seekingalpha.com/article/4441533-netflix-calculating-its-intrinsic-value\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://seekingalpha.com/article/4441533-netflix-calculating-its-intrinsic-value","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154159969","content_text":"Summary\n\nOur forecasts are based purely on fundamentals.\nWe expect Netflix to see margin expansion going forward.\nNetflix is undervalued under current market conditions.\n\nPascal Le Segretain/Getty Images News\nNetflix Inc (NFLX) has the potential to perform well. However, we highlight what you need to consider before jumping into the stock. We base our forecast purely on the company's fundamentals. By doing so, we are able to point to the specific growth drivers rooted in numbers as opposed to perceived potential. In addition, we believe that Netflix's margins will expand going forward. Using the fundamentals allows us to more reasonably estimate the company's margin expansion.\nValuation\nForecasting is not easy and it's difficult to be precise. However, the point of forecasting is not to be right but to be reasonable. Our projections are based on the company's fundamentals. We try to determine what growth rates the company can fundamentally sustain up until 2025.\nWe will begin with the growth rate we expect for fiscal year 2021. The first thing we need is to determine what will constitute as reinvestment. For Netflix, it will be research and development, marketing, capital expenditures, net investment in content, and change in net working capital.\nPlease note that we measure net investment in content as the cash spent on developing content subtracted by the amortization of previously developed content. Our assumption is that the amortized amount is the \"maintenance content\" needed to maintain the interest of current users and doesn't contribute to growth. The net investment in content is what we consider the \"growth content\" that contributes to attracting new users or justifying price increases.\nIn addition, that depreciation and amortization expense is subtracted from the reinvestment rate as it is used as a proxy for maintenance capex that does not contribute to growth.\nThe next step is to find the revenue-to-capital ratio. This measures how much revenue a company generates for each dollar in capital. Once we have both numbers, we multiply them to calculate the fundamental growth rate.\nSource: Author\nIn the picture above, we see that the reinvestment rate was 21.44% of revenue and revenue to capital was 93.39%. Therefore, the fundamental growth rate for fiscal year 2021 equals 20.02%. This is slightly above analysts' expectations but by very little.\nThe next step is to determine the degree of operating leverage, which is a multiple that measures how much the operating income of a company will change in response to a change in sales. Netflix has had a ratio of over 2 over the past several years. To be conservative, we will use 2 and reduce it each year. In addition, we did the same thing with gross margins using a starting point of 1.08.\nAs the EBIT margin increases, the reinvestment rate decreases because R&D and marketing expenses become a smaller percentage of revenue, resulting in a slowdown of growth. We measure this slowdown by setting R&D and marketing to 70% of total operating expenses (percentage in fiscal year 2020). We then calculate the future fundamental growth rates with the projected numbers as follows:\nSource: Author\nWe used the average capital expenditure and D&A margins of the last three years. Now we will input these numbers into a DCF using the company's weighted average cost of capital of 5% based on current market conditions.Please note that we grouped net content investment with capital expenditures.\nSource: Author using Finbox tools\nAs you can see, with a 5% discount rate, 21% tax rate, 2% terminal growth rate, and a forecast based on fundamentals, the company has the potential for 24.6% upside. Of course, discount rates are always changing and not everyone likes to use current discount rates. Therefore, we made the chart below to demonstrate the fair value at each discount rate and terminal growth rate:\nSource: Author\nAs you can see, if interest rates stay low for an extended period of time, Netflix can potentially see solid upside. However, there isn't much room for changes in the discount rates, and therefore should be careful if you believe discount rates are going up.\nChecking for Consistencies in the Forecast\nLet's make sure everything makes sense in the forecast. We'll begin with revenue growth. You can see that we expect revenue growth to accelerate in 2022 before gradually decreasing in the following years. This is because we expect Netflix to increase its net content investment in 2021. The company has stated that it willincrease overall investment in contentto $17 billion, up from $11.8 billion in 2020. This consequently leads to a higher reinvestment rate and the potential to accelerate revenue growth. This seems reasonable to us because it has happened to Netflix in the past where revenue growth has accelerated.\nSource: Author\nIn addition, the net content investment in our forecast is similar to the absolute amounts Netflix spent pre-pandemic.\nFurthermore, management expects free cash flow for this year to be break even or slightly higher. It's hard to say what slightly above means for the management team. Although $119 million is exactly slightly above breakeven, it is still significantly less than what it was in 2020. However, management hasn't specified whether it is unlevered or levered free cash flow and it is possible that unlevered free cash flow (which is what we used) might be higher. It is also possible that Netflix might have a stronger than expected second half. Regardless, the $119 million is immaterial to the valuation overall.\nGrowth Catalysts\nAn obvious growth catalyst that impacts our forecast is the company's increase in content spend. Content is the most important factor when it comes to entertainment-based businesses. Netflix can have the most technologically advanced platform in the world but, if the content is boring, then nobody would use it.\nIn addition, although streaming has become increasingly popular, cable still accounts for the largest share of total tv time in the US:\n\nAs you can see, the streaming market as a whole is only 27% of the total share. Despite all the talk about increasing competition, there is still plenty of room for the streaming segment to grow as a whole. Therefore, even if Netflix loses market share to other streamers, it will still be able to grow in absolute terms.\nFinally, Netflix's venture intovideo gamescould be beneficial if executed correctly. However, we don't have too much conviction in this idea just yet, which we talk more about in the \"risks\" section below.\nRisks\nWe will begin with video games. The video game industry is very tough. With all the money that Amazon.com Inc (AMZN) generates, it hasstruggled to releasea successful game since starting the division in 2014. Likewise, Alphabet Inc (GOOG) has suffered asimilar problem. This implies that developing successful video games is not as easy as throwing money at developers and requires a certain level of specialization.\nSpeaking of throwing money, Netflix's increased spend on content may not yield positive results if it is rushed. Thisarticledemonstrates that people can notice when projects are rushed. Although the article is from 2019, it is an important reminder that the quality of the content is likely to be more important than the quantity. If Netflix fails to deliver on quality, it could see subscriber counts drop.\nFinal Thoughts\nNetflix is undervalued under current market conditions; however, it doesn't provide enough of a margin of safety if the interest/discount rates increase. Thus, although Netflix may continue to do well, we will stay on the sidelines for now.","news_type":1,"symbols_score_info":{"NFLX":0.9}},"isVote":1,"tweetType":1,"viewCount":686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809593548,"gmtCreate":1627376575084,"gmtModify":1703488702432,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809593548","repostId":"800862044","repostType":1,"repost":{"id":800862044,"gmtCreate":1627291505685,"gmtModify":1703486908679,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/44a4f89726b3f6319d06a0075bf9ff76","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"【曬單有獎】曬曬我虧的最多的股票～","htmlText":"本來以爲上週五已經到了黃金坑了，結果發現坑下還有鑽石底，在Black&nbsp;Friday之後，居然還有Black&nbsp;Monday, 真的是跌出了股災的感覺。A股方面：創業板一度崩了5%，上證暴跌超3%，上證50一度跌近5%，整個市場超3000個股下跌，外資更是瘋狂出逃了100億。隨着“雙減”政策落地，對在線教育的商業模式和估值體系有“毀滅性”的衝擊。<a target=\"_blank\" href=\"https://laohu8.com/S/EDU\">$新東方(EDU)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/TAL\">$好未來(TAL)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GOTU\">$高途(GOTU)$</a> 齊齊領跌市場。不過令人意外的是白酒和醫美板塊也跌了，爲何暴跌，最火的段子解釋了一切。港股方面，恆生指數暴跌近1000點，科技指數暴跌近6%，昔日的大牛股騰訊、美團、阿里巴巴、快手，全部咔咔的跌，真的是越過山丘，跌跌不休。美股盤前再度延續了週五的走勢，先跌爲敬。要說爲啥下跌，機智的網友們也給出了最佳答案。哎，你還要我怎樣？還要我怎樣？歡迎大家在下帖留言，聊聊你的股票今天表現如何？曬曬你虧了多少錢？，我們一起抱團取暖、相互安慰~ 【參與方式】 在本貼評論區留言曬出持倉分享圖即可參與！ 如何參與曬單？ 點擊APP的“交易”頁面，選擇交易的股票，點擊持倉盈虧分享，即可解鎖萌萌的小虎表情包。（更新到6.8.9以上版本的虎友們，除了分享單隻股票漲跌幅之外，還可以分享你賺、虧了多少錢哦）  【活動獎勵】 老虎社區第7屆比慘大賽正式開始嘍，歡迎大家在本帖下方留言，聊聊你的股票今天表現如何？曬曬你虧/賺了多少錢？我們會選取盈虧最多或者最有","listText":"本來以爲上週五已經到了黃金坑了，結果發現坑下還有鑽石底，在Black&nbsp;Friday之後，居然還有Black&nbsp;Monday, 真的是跌出了股災的感覺。A股方面：創業板一度崩了5%，上證暴跌超3%，上證50一度跌近5%，整個市場超3000個股下跌，外資更是瘋狂出逃了100億。隨着“雙減”政策落地，對在線教育的商業模式和估值體系有“毀滅性”的衝擊。<a target=\"_blank\" href=\"https://laohu8.com/S/EDU\">$新東方(EDU)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/TAL\">$好未來(TAL)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/GOTU\">$高途(GOTU)$</a> 齊齊領跌市場。不過令人意外的是白酒和醫美板塊也跌了，爲何暴跌，最火的段子解釋了一切。港股方面，恆生指數暴跌近1000點，科技指數暴跌近6%，昔日的大牛股騰訊、美團、阿里巴巴、快手，全部咔咔的跌，真的是越過山丘，跌跌不休。美股盤前再度延續了週五的走勢，先跌爲敬。要說爲啥下跌，機智的網友們也給出了最佳答案。哎，你還要我怎樣？還要我怎樣？歡迎大家在下帖留言，聊聊你的股票今天表現如何？曬曬你虧了多少錢？，我們一起抱團取暖、相互安慰~ 【參與方式】 在本貼評論區留言曬出持倉分享圖即可參與！ 如何參與曬單？ 點擊APP的“交易”頁面，選擇交易的股票，點擊持倉盈虧分享，即可解鎖萌萌的小虎表情包。（更新到6.8.9以上版本的虎友們，除了分享單隻股票漲跌幅之外，還可以分享你賺、虧了多少錢哦）  【活動獎勵】 老虎社區第7屆比慘大賽正式開始嘍，歡迎大家在本帖下方留言，聊聊你的股票今天表現如何？曬曬你虧/賺了多少錢？我們會選取盈虧最多或者最有","text":"本來以爲上週五已經到了黃金坑了，結果發現坑下還有鑽石底，在Black Friday之後，居然還有Black Monday, 真的是跌出了股災的感覺。A股方面：創業板一度崩了5%，上證暴跌超3%，上證50一度跌近5%，整個市場超3000個股下跌，外資更是瘋狂出逃了100億。隨着“雙減”政策落地，對在線教育的商業模式和估值體系有“毀滅性”的衝擊。$新東方(EDU)$ $好未來(TAL)$ $高途(GOTU)$ 齊齊領跌市場。不過令人意外的是白酒和醫美板塊也跌了，爲何暴跌，最火的段子解釋了一切。港股方面，恆生指數暴跌近1000點，科技指數暴跌近6%，昔日的大牛股騰訊、美團、阿里巴巴、快手，全部咔咔的跌，真的是越過山丘，跌跌不休。美股盤前再度延續了週五的走勢，先跌爲敬。要說爲啥下跌，機智的網友們也給出了最佳答案。哎，你還要我怎樣？還要我怎樣？歡迎大家在下帖留言，聊聊你的股票今天表現如何？曬曬你虧了多少錢？，我們一起抱團取暖、相互安慰~ 【參與方式】 在本貼評論區留言曬出持倉分享圖即可參與！ 如何參與曬單？ 點擊APP的“交易”頁面，選擇交易的股票，點擊持倉盈虧分享，即可解鎖萌萌的小虎表情包。（更新到6.8.9以上版本的虎友們，除了分享單隻股票漲跌幅之外，還可以分享你賺、虧了多少錢哦） 【活動獎勵】 老虎社區第7屆比慘大賽正式開始嘍，歡迎大家在本帖下方留言，聊聊你的股票今天表現如何？曬曬你虧/賺了多少錢？我們會選取盈虧最多或者最有","images":[{"img":"https://static.tigerbbs.com/56d1d61084247d955b3196f8e9717aa0","width":"1784","height":"1088"},{"img":"https://static.tigerbbs.com/42c494b7e30cdd938ba31081d68ea577","width":"1538","height":"478"},{"img":"https://static.tigerbbs.com/d68747e13b19a4b07f1d5c974abefa84","width":"730","height":"570"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/800862044","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":638,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809599985,"gmtCreate":1627376437647,"gmtModify":1703488699845,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Consumers are back in business, a good sign","listText":"Consumers are back in business, a good sign","text":"Consumers are back in business, a good sign","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809599985","repostId":"1175986847","repostType":4,"repost":{"id":"1175986847","kind":"news","pubTimestamp":1627371958,"share":"https://ttm.financial/m/news/1175986847?lang=en_US&edition=fundamental","pubTime":"2021-07-27 15:45","market":"us","language":"en","title":"LVMH shares edge higher as sales and profits rise","url":"https://stock-news.laohu8.com/highlight/detail?id=1175986847","media":"Reuters","summary":"PARIS (Reuters) - LVMH’s shares eged higher on Tuesday after the world’s biggest luxury goods group ","content":"<p>PARIS (Reuters) - LVMH’s shares eged higher on Tuesday after the world’s biggest luxury goods group posted higher sales and profits, driven by surging sales of fashion lines and handbags by Dior, Fendi and Louis Vuitton.</p>\n<p>LVMH shares were up 0.3% in early session trading.</p>\n<p>“We are encouraged by Louis Vuitton and Dior’s exceptional brand positioning across regions and sustained local luxury consumer demand,” wrote brokerage Cowen &amp; Company, which kept an ‘outperform’ rating on LVMH shares.</p>\n<p>The luxury goods industry is recovering from the COVID-19 crisis, which shut down global travel and temporarily closed stores, and LVMH has benefited more than most, using its heft to spend on marketing and social media campaigns when some of its smaller rivals are still struggling to get back on their feet.</p>\n<p>Overall sales at LVMH, which also owns champagne and cosmetics labels, rose by 84% year-on-year in the second quarter on a like-for-like basis, which strips out currency swings, and stood at 14.7 billion euros ($17.33 billion).</p>\n<p>Operating profit in the first six months of this year more than quadrupled compared with a year ago, beating expectations among analysts polled by Refinitiv.</p>\n<p>“We think much of this will be repeated in H2 in the absence of a sector momentum shift: as long as the sector performs, LVMH will perform better,” wrote brokerage Jefferies, which kept a ‘buy’ rating on LVMH shares.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LVMH shares edge higher as sales and profits rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLVMH shares edge higher as sales and profits rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/lvmh-results/lvmh-shares-edge-higher-as-sales-and-profits-rise-idUSFWN2P30JJ><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS (Reuters) - LVMH’s shares eged higher on Tuesday after the world’s biggest luxury goods group posted higher sales and profits, driven by surging sales of fashion lines and handbags by Dior, ...</p>\n\n<a href=\"https://www.reuters.com/article/lvmh-results/lvmh-shares-edge-higher-as-sales-and-profits-rise-idUSFWN2P30JJ\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LB":"LandBridge Co. LLC"},"source_url":"https://www.reuters.com/article/lvmh-results/lvmh-shares-edge-higher-as-sales-and-profits-rise-idUSFWN2P30JJ","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175986847","content_text":"PARIS (Reuters) - LVMH’s shares eged higher on Tuesday after the world’s biggest luxury goods group posted higher sales and profits, driven by surging sales of fashion lines and handbags by Dior, Fendi and Louis Vuitton.\nLVMH shares were up 0.3% in early session trading.\n“We are encouraged by Louis Vuitton and Dior’s exceptional brand positioning across regions and sustained local luxury consumer demand,” wrote brokerage Cowen & Company, which kept an ‘outperform’ rating on LVMH shares.\nThe luxury goods industry is recovering from the COVID-19 crisis, which shut down global travel and temporarily closed stores, and LVMH has benefited more than most, using its heft to spend on marketing and social media campaigns when some of its smaller rivals are still struggling to get back on their feet.\nOverall sales at LVMH, which also owns champagne and cosmetics labels, rose by 84% year-on-year in the second quarter on a like-for-like basis, which strips out currency swings, and stood at 14.7 billion euros ($17.33 billion).\nOperating profit in the first six months of this year more than quadrupled compared with a year ago, beating expectations among analysts polled by Refinitiv.\n“We think much of this will be repeated in H2 in the absence of a sector momentum shift: as long as the sector performs, LVMH will perform better,” wrote brokerage Jefferies, which kept a ‘buy’ rating on LVMH shares.","news_type":1,"symbols_score_info":{"LB":0.9}},"isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809278962,"gmtCreate":1627375253956,"gmtModify":1703488673884,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Another blood bath!&nbsp;","listText":"Another blood bath!&nbsp;","text":"Another blood bath!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809278962","repostId":"1142907091","repostType":4,"repost":{"id":"1142907091","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627373467,"share":"https://ttm.financial/m/news/1142907091?lang=en_US&edition=fundamental","pubTime":"2021-07-27 16:11","market":"us","language":"en","title":"Hot Chinese concept stocks resumed downward in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142907091","media":"Tiger Newspress","summary":"Hot Chinese concept stocks resumed downward in premarket trading.Bilibili and NetEase fell 7%,DiDi G","content":"<p>Hot Chinese concept stocks resumed downward&nbsp;in premarket trading.Bilibili&nbsp;and&nbsp;NetEase&nbsp;fell&nbsp;7%,DiDi Global,JD.com&nbsp;and&nbsp;Pinduoduo&nbsp;fell&nbsp;6%,Baidu&nbsp;fell&nbsp;5%,Xpeng Motors&nbsp;fell&nbsp;4%,Alibaba,Nio&nbsp;and Li Auto&nbsp;fell&nbsp;3%.</p>\n<p><img src=\"https://static.tigerbbs.com/6d3f423af5595483b1ce34aa42d60cc7\" tg-width=\"355\" tg-height=\"602\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese concept stocks resumed downward in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese concept stocks resumed downward in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-27 16:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hot Chinese concept stocks resumed downward&nbsp;in premarket trading.Bilibili&nbsp;and&nbsp;NetEase&nbsp;fell&nbsp;7%,DiDi Global,JD.com&nbsp;and&nbsp;Pinduoduo&nbsp;fell&nbsp;6%,Baidu&nbsp;fell&nbsp;5%,Xpeng Motors&nbsp;fell&nbsp;4%,Alibaba,Nio&nbsp;and Li Auto&nbsp;fell&nbsp;3%.</p>\n<p><img src=\"https://static.tigerbbs.com/6d3f423af5595483b1ce34aa42d60cc7\" tg-width=\"355\" tg-height=\"602\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","DIDI":"滴滴(已退市)","LI":"理想汽车","BIDU":"百度","NIO":"蔚来","XPEV":"小鹏汽车","JD":"京东","PDD":"拼多多"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142907091","content_text":"Hot Chinese concept stocks resumed downward in premarket trading.Bilibili and NetEase fell 7%,DiDi Global,JD.com and Pinduoduo fell 6%,Baidu fell 5%,Xpeng Motors fell 4%,Alibaba,Nio and Li Auto fell 3%.","news_type":1,"symbols_score_info":{"BIDU":0.9,"XPEV":0.9,"LI":0.9,"JD":0.9,"NIO":0.9,"BABA":0.9,"PDD":0.9,"DIDI":0.9}},"isVote":1,"tweetType":1,"viewCount":641,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177819608,"gmtCreate":1627194112504,"gmtModify":1703485427676,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Reacted too slowly","listText":"Reacted too slowly","text":"Reacted too slowly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/177819608","repostId":"1176552691","repostType":4,"repost":{"id":"1176552691","kind":"news","pubTimestamp":1627183789,"share":"https://ttm.financial/m/news/1176552691?lang=en_US&edition=fundamental","pubTime":"2021-07-25 11:29","market":"us","language":"en","title":"Is IBM Stock Undervalued Or Overvalued? What To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=1176552691","media":"seekingalpha","summary":"Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.","content":"<p><b>Summary</b></p>\n<ul>\n <li>IBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.</li>\n <li>Prior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 quarters.</li>\n <li>More transparency is needed regarding the Kyndryl spinoff.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c798e0536c6804d44b195f6f349fab5\" tg-width=\"1536\" tg-height=\"1044\" width=\"100%\" height=\"auto\"><span>Ethan Miller/Getty Images News</span></p>\n<p>International Business Machines Corporation (IBM) is a company in transition. Unfortunately for investors, the transition has been in place for the better part of a decade. Those turnaround efforts include investments in cloud computing and artificial intelligence and the divestiture of legacy businesses. While there are now signs of green shoots, it is yet to be seen as to whether the seeds sown have fallen on rocky ground.</p>\n<p>Although the company has a rapidly growing business in hybrid cloud offerings, and a potential growth engine in quantum computing, it faces intense competition in the former industry and uncertain prospects in the latter. Most of the firm’s other businesses are in the doldrums, so IBM’s growth prospects are opaque.</p>\n<p>What is certain is that as of today, IBM has a reasonable and diminishing debt load and strong free cash flow.</p>\n<p>Management is attempting to address growth concerns in part by focusing on the firm’s cloud offerings, while it spins off its managed infrastructure business. That company will be named Kyndryl. However, the debt which the new entity will shoulder, along with the portion of the current dividend that it will carry, has not been divulged.</p>\n<p><b>Recent Quarterly Results</b></p>\n<p>IBM&nbsp;reported&nbsp;Q2 results last Monday. With non-GAAP EPS of $2.33, the company beat estimates by $0.04.</p>\n<p>Revenue of $18.7 billion was flat when adjusted for currency and divestitures.</p>\n<p>The negative side of the report had Systems revenue declining by 7%. However, this was largely due to the normal IBM Z mainframe cycle, down 13% year over year.</p>\n<p>The global financing division, which represents a low single digit percentage of overall revenues, was down 9%. Global technology services, which represents roughly a third of overall revenue and will largely be spun off as Kyndryl, had flattish growth.</p>\n<p>The positive side of the report had Cloud &amp; Cognitive Software cloud revenue up 29% and Global Business Services cloud revenue up 35%. Total cloud revenue of $27 billion increased by 15% over the last 12 months, while cloud revenue grew 13% in the quarter to $7.0 billion.</p>\n<p>Net cash from operating activities hit $17.7 billion, and adjusted free cash flow totaled $11 billion over the last 12 months.</p>\n<p>Since year-end 2020, the company has reduced debt by $6.4 billion.</p>\n<p>Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021.</p>\n<p><b>Where IBM Stands Tall</b></p>\n<p>IBM is viewed by many as at best a third rate IT company and at worst as a dinosaur, headed towards extinction.</p>\n<p>It is evident that the company’s revenues have declined for years; however, to accurately assess the stock, investors must understand that IBM’s legacy businesses have many strengths.</p>\n<p>For example, IBM is the world’s largest IT services company and the dominant provider of mainframes. Among the Fortune 50 companies, 47 are IBM clients.</p>\n<p>Half of the world’s wireless connections are handled by the firm.</p>\n<p>IBM's mainframe systems process nearly 90% of the globe’s credit card transactions, and 97% of the world's largest banks rely on IBM products and services. Consequently, twenty-nine billion ATM transactions are processed annually using IBM systems.</p>\n<p>Eight out of 10 global retailers rely on IBM products and services while 80% of the travel industry's reservations run through IBM systems. That results in 4 billion flight reservations being processed using the company’s IT services.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7ace4f1436fd2697c5ad266b5017e1dd\" tg-width=\"960\" tg-height=\"721\" width=\"100%\" height=\"auto\"><span>Source: Forbes</span></p>\n<p>It is evident that IBM has a massive customer base that provides large scale recurring revenues. In many cases, moving to competitors' offerings would mean risking the transfer of sensitive information, a move many are not willing to take.</p>\n<p>However, with the transition to cloud services and open source software, there is an increased adoption by firms of mix and match IT infrastructures. In turn, this is eroding IBM’s competitive advantage associated with customer switching costs.</p>\n<p><b>The Sources Of Potential Growth</b></p>\n<p>Investors are generally aware of IBM's effort to drive growth through its hybrid cloud offerings. However, when questioned at JPMorgan’s recent investor conference, CFO Jim Kavanaugh&nbsp;provided insight&nbsp;into how hybrid cloud drives revenue in some of IBM’s other divisions.</p>\n<blockquote>\n For every $1 (in business) we land on a hybrid cloud platform, we see $3 to $5 of software drag and $6 to $8 of services drag overall.\n</blockquote>\n<p>Of course, Kavanaugh is using drag to refer to increased revenue in software and services associated with adoption of IBM’s hybrid cloud. If Kavanaugh’s claims are accurate, that means every dollar spent on the company’s hybrid cloud platform translates into $9 to $13 in additional revenue from the firm’s software and services offerings.</p>\n<p>Because hybrid cloud uses a mix of on-premises private cloud and public cloud services, it offers clients a degree of data privacy. This is of particular concern for customers in healthcare and financial services. Consequently, I would posit that IBM might have an advantage in competing with other hybrid cloud providers as it has extensive relationships within those industries.</p>\n<p>I reviewed a variety of prognostications regarding projected growth rates for the hybrid cloud market. The most recent study, which also falls in the middle of other predictions, is by Mordor Intelligence. That firm&nbsp;forecasts&nbsp;a CAGR of 18.73% from 2021 through 2026.</p>\n<p>Investors should be aware that the major operators in this space are Cisco (CSCO), Hewlett Packard (HPE), Amazon (AMZN), Citrix Systems (CTXS), and IBM.</p>\n<p>The following chart provides a record of the firm’s total cloud growth over the last six quarters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5fc85156e70f6caf8ae809f76126a723\" tg-width=\"576\" tg-height=\"336\" width=\"100%\" height=\"auto\"><span>Source: Company reports / Chart by Author</span></p>\n<p>Aside from cloud, there is another source of potential growth, although it is unlikely to materialize soon.</p>\n<p>Early in 2019, IBM&nbsp;introduced&nbsp;the Q System One. IBM Q systems are the world's first quantum computer designed for scientific and commercial use.</p>\n<p>Pardon the pun, but quantum computers represent a quantum leap in technology. Prescient And Strategic Intelligence&nbsp;forecasts&nbsp;a CAGR of 56% for the industry through 2030 with the quantum computer market share reaching nearly $65 billion.</p>\n<p>For additional insights regarding quantum computing and IBM’s position within that industry, I point you to&nbsp;my article, “IBM: Why My Eye Is Fixed On Big Blue.”</p>\n<p><b>Understanding Kyndryl</b></p>\n<p>Once&nbsp;Kyndryl&nbsp;is launched, it will have more than 90,000 employees and more than 4,600 customers in 115 countries. With a $60 billion services backlog, the new entity will begin with projected revenues of $19 billion. At twice the size of its closest competitor, the company will be the world’s largest managed infrastructure services provider.</p>\n<p>The split will&nbsp;transform&nbsp;IBM from a company that pulls half of its revenue from services to a firm with its software and solutions businesses generating over half of its revenue on a recurring basis.</p>\n<p>Global Business Services, which currently constitutes 22% of the company’s revenue, will&nbsp;account&nbsp;for over 40% of sales. Here it is important to note that the division grew revenue by 12% year over year in the last quarter.</p>\n<p>IBM will retain Red Hat and its solution provider business, the systems businesses, and its mission-critical public cloud service, and a software portfolio focused on big data, AI, and security.</p>\n<p>Initially, the two companies will each be the largest customer of the other.</p>\n<p>What remains to be known regarding the spinoff is how much debt each company will shoulder, and the share of the dividend that the companies will pay. Krishna stated the two companies will work together to sustain the current payout level.</p>\n<p><b>Has IBM Turned The Corner?</b></p>\n<p>Anyone who follows IBM knows the company has experienced an extended period of poor results. The following chart provides a record of the firm’s quarterly FCF over the last fourteen quarters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/60cc8b82052f97dd449205999ee30711\" tg-width=\"577\" tg-height=\"337\" width=\"100%\" height=\"auto\"><span>Source: Data from ycharts / chart by author</span></p>\n<p>While this is not proof positive that the company is back on track, the recent trend is at least encouraging.</p>\n<p>In 2020, IBM generated $10.8 billion in free cash flow. Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021. This excludes $3 billion in structural impacts related to the Kyndryl spinoff.</p>\n<p>The CEO&nbsp;recently stated&nbsp;he expects IBM to generate $12 billion to $13 billion in FCF in 2022.</p>\n<p><b>Debt And Dividend</b></p>\n<p>While investors can rightfully complain of a variety of management moves over the years, the firm has maintained a reasonable debt profile while engaging in a number of acquisitions.</p>\n<p>The company has reduced the debt by roughly $18 billion since its peak in mid-2019. IBM maintains an investment level credit rating, and the following chart provides a record of the company’s progress paying down debt of late.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b73e613157c486a5f5e8306546121971\" tg-width=\"1280\" tg-height=\"720\" width=\"100%\" height=\"auto\"><span>Source: IBM Presentation</span></p>\n<p>IBM has a yield of 4.64%, a payout ratio a bit below 61%, and a 5 year dividend growth rate of 4.26%. As previously noted, following the spinoff of Kyndryl, the two companies will team to provide a payout equivalent to the current dividend.</p>\n<p><b>Is IBM Stock Overvalued?</b></p>\n<p>IBM shares trade for $141.13. The average 12 month price target of 8 analysts is $153.50. The price target of the 3 analysts rating the stock since the last earnings report is $151.33.</p>\n<p>IBM has a P/E of 24.05x and a forward P/E of 17.67x. This compares to its five year averages of 16.42x and 13.25x respectively. It is well below the sector average which is in the low thirties for both metrics.</p>\n<p>The 3 to 5 year PEG provided by Seeking Alpha Premium is 1.16x. Schwab calculates a PEG of 1.49x, and Yahoo does not provide a PEG ratio.</p>\n<p>I believe the current P/E ratios for the stock reflect investors anticipating increased growth for IBM once the spinoff is complete. The PEG ratios show the stock is reasonably valued.</p>\n<p><b>Is IBM Stock A Good Long-Term Investment?</b></p>\n<p>IBM has an entrenched but evolving position among many of the largest companies on the globe. Unfortunately, the cloud, which is seen as the company’s primary avenue for growth, could also lead to a slow deterioration in some of the firm’s legacy businesses.</p>\n<p>That the cloud business has been growing at a rapid pace is manifest: IBM can now boast of over 3,200 clients using the firm’s hybrid cloud platform. That is nearly four times the number just prior to the Red Hat acquisition.</p>\n<p>If management’s claims are accurate, the hybrid cloud platform will create robust growth in the software and services division’s revenues. When combined with the spinoff of Kyndryl’s slow growing managed infrastructure services business, it is reasonable to believe IBM will witness increased growth.</p>\n<p>IBM has a solid balance sheet, a robust yield, and when viewed using PEG ratios as a basis for valuing the stock, the shares are trading at a bit of a discount.</p>\n<p>All considered, I rate IBM as a BUY.</p>\n<p>I think the worst case short to mid-term scenario is that the company experiences slow growth while investors collect a rather robust dividend.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is IBM Stock Undervalued Or Overvalued? What To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs IBM Stock Undervalued Or Overvalued? What To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-25 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.\nPrior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 ...</p>\n\n<a href=\"https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM"},"source_url":"https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176552691","content_text":"Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.\nPrior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 quarters.\nMore transparency is needed regarding the Kyndryl spinoff.\n\nEthan Miller/Getty Images News\nInternational Business Machines Corporation (IBM) is a company in transition. Unfortunately for investors, the transition has been in place for the better part of a decade. Those turnaround efforts include investments in cloud computing and artificial intelligence and the divestiture of legacy businesses. While there are now signs of green shoots, it is yet to be seen as to whether the seeds sown have fallen on rocky ground.\nAlthough the company has a rapidly growing business in hybrid cloud offerings, and a potential growth engine in quantum computing, it faces intense competition in the former industry and uncertain prospects in the latter. Most of the firm’s other businesses are in the doldrums, so IBM’s growth prospects are opaque.\nWhat is certain is that as of today, IBM has a reasonable and diminishing debt load and strong free cash flow.\nManagement is attempting to address growth concerns in part by focusing on the firm’s cloud offerings, while it spins off its managed infrastructure business. That company will be named Kyndryl. However, the debt which the new entity will shoulder, along with the portion of the current dividend that it will carry, has not been divulged.\nRecent Quarterly Results\nIBM reported Q2 results last Monday. With non-GAAP EPS of $2.33, the company beat estimates by $0.04.\nRevenue of $18.7 billion was flat when adjusted for currency and divestitures.\nThe negative side of the report had Systems revenue declining by 7%. However, this was largely due to the normal IBM Z mainframe cycle, down 13% year over year.\nThe global financing division, which represents a low single digit percentage of overall revenues, was down 9%. Global technology services, which represents roughly a third of overall revenue and will largely be spun off as Kyndryl, had flattish growth.\nThe positive side of the report had Cloud & Cognitive Software cloud revenue up 29% and Global Business Services cloud revenue up 35%. Total cloud revenue of $27 billion increased by 15% over the last 12 months, while cloud revenue grew 13% in the quarter to $7.0 billion.\nNet cash from operating activities hit $17.7 billion, and adjusted free cash flow totaled $11 billion over the last 12 months.\nSince year-end 2020, the company has reduced debt by $6.4 billion.\nManagement guides for adjusted free cash flow of $11 billion to $12 billion in 2021.\nWhere IBM Stands Tall\nIBM is viewed by many as at best a third rate IT company and at worst as a dinosaur, headed towards extinction.\nIt is evident that the company’s revenues have declined for years; however, to accurately assess the stock, investors must understand that IBM’s legacy businesses have many strengths.\nFor example, IBM is the world’s largest IT services company and the dominant provider of mainframes. Among the Fortune 50 companies, 47 are IBM clients.\nHalf of the world’s wireless connections are handled by the firm.\nIBM's mainframe systems process nearly 90% of the globe’s credit card transactions, and 97% of the world's largest banks rely on IBM products and services. Consequently, twenty-nine billion ATM transactions are processed annually using IBM systems.\nEight out of 10 global retailers rely on IBM products and services while 80% of the travel industry's reservations run through IBM systems. That results in 4 billion flight reservations being processed using the company’s IT services.\nSource: Forbes\nIt is evident that IBM has a massive customer base that provides large scale recurring revenues. In many cases, moving to competitors' offerings would mean risking the transfer of sensitive information, a move many are not willing to take.\nHowever, with the transition to cloud services and open source software, there is an increased adoption by firms of mix and match IT infrastructures. In turn, this is eroding IBM’s competitive advantage associated with customer switching costs.\nThe Sources Of Potential Growth\nInvestors are generally aware of IBM's effort to drive growth through its hybrid cloud offerings. However, when questioned at JPMorgan’s recent investor conference, CFO Jim Kavanaugh provided insight into how hybrid cloud drives revenue in some of IBM’s other divisions.\n\n For every $1 (in business) we land on a hybrid cloud platform, we see $3 to $5 of software drag and $6 to $8 of services drag overall.\n\nOf course, Kavanaugh is using drag to refer to increased revenue in software and services associated with adoption of IBM’s hybrid cloud. If Kavanaugh’s claims are accurate, that means every dollar spent on the company’s hybrid cloud platform translates into $9 to $13 in additional revenue from the firm’s software and services offerings.\nBecause hybrid cloud uses a mix of on-premises private cloud and public cloud services, it offers clients a degree of data privacy. This is of particular concern for customers in healthcare and financial services. Consequently, I would posit that IBM might have an advantage in competing with other hybrid cloud providers as it has extensive relationships within those industries.\nI reviewed a variety of prognostications regarding projected growth rates for the hybrid cloud market. The most recent study, which also falls in the middle of other predictions, is by Mordor Intelligence. That firm forecasts a CAGR of 18.73% from 2021 through 2026.\nInvestors should be aware that the major operators in this space are Cisco (CSCO), Hewlett Packard (HPE), Amazon (AMZN), Citrix Systems (CTXS), and IBM.\nThe following chart provides a record of the firm’s total cloud growth over the last six quarters.\nSource: Company reports / Chart by Author\nAside from cloud, there is another source of potential growth, although it is unlikely to materialize soon.\nEarly in 2019, IBM introduced the Q System One. IBM Q systems are the world's first quantum computer designed for scientific and commercial use.\nPardon the pun, but quantum computers represent a quantum leap in technology. Prescient And Strategic Intelligence forecasts a CAGR of 56% for the industry through 2030 with the quantum computer market share reaching nearly $65 billion.\nFor additional insights regarding quantum computing and IBM’s position within that industry, I point you to my article, “IBM: Why My Eye Is Fixed On Big Blue.”\nUnderstanding Kyndryl\nOnce Kyndryl is launched, it will have more than 90,000 employees and more than 4,600 customers in 115 countries. With a $60 billion services backlog, the new entity will begin with projected revenues of $19 billion. At twice the size of its closest competitor, the company will be the world’s largest managed infrastructure services provider.\nThe split will transform IBM from a company that pulls half of its revenue from services to a firm with its software and solutions businesses generating over half of its revenue on a recurring basis.\nGlobal Business Services, which currently constitutes 22% of the company’s revenue, will account for over 40% of sales. Here it is important to note that the division grew revenue by 12% year over year in the last quarter.\nIBM will retain Red Hat and its solution provider business, the systems businesses, and its mission-critical public cloud service, and a software portfolio focused on big data, AI, and security.\nInitially, the two companies will each be the largest customer of the other.\nWhat remains to be known regarding the spinoff is how much debt each company will shoulder, and the share of the dividend that the companies will pay. Krishna stated the two companies will work together to sustain the current payout level.\nHas IBM Turned The Corner?\nAnyone who follows IBM knows the company has experienced an extended period of poor results. The following chart provides a record of the firm’s quarterly FCF over the last fourteen quarters.\nSource: Data from ycharts / chart by author\nWhile this is not proof positive that the company is back on track, the recent trend is at least encouraging.\nIn 2020, IBM generated $10.8 billion in free cash flow. Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021. This excludes $3 billion in structural impacts related to the Kyndryl spinoff.\nThe CEO recently stated he expects IBM to generate $12 billion to $13 billion in FCF in 2022.\nDebt And Dividend\nWhile investors can rightfully complain of a variety of management moves over the years, the firm has maintained a reasonable debt profile while engaging in a number of acquisitions.\nThe company has reduced the debt by roughly $18 billion since its peak in mid-2019. IBM maintains an investment level credit rating, and the following chart provides a record of the company’s progress paying down debt of late.\nSource: IBM Presentation\nIBM has a yield of 4.64%, a payout ratio a bit below 61%, and a 5 year dividend growth rate of 4.26%. As previously noted, following the spinoff of Kyndryl, the two companies will team to provide a payout equivalent to the current dividend.\nIs IBM Stock Overvalued?\nIBM shares trade for $141.13. The average 12 month price target of 8 analysts is $153.50. The price target of the 3 analysts rating the stock since the last earnings report is $151.33.\nIBM has a P/E of 24.05x and a forward P/E of 17.67x. This compares to its five year averages of 16.42x and 13.25x respectively. It is well below the sector average which is in the low thirties for both metrics.\nThe 3 to 5 year PEG provided by Seeking Alpha Premium is 1.16x. Schwab calculates a PEG of 1.49x, and Yahoo does not provide a PEG ratio.\nI believe the current P/E ratios for the stock reflect investors anticipating increased growth for IBM once the spinoff is complete. The PEG ratios show the stock is reasonably valued.\nIs IBM Stock A Good Long-Term Investment?\nIBM has an entrenched but evolving position among many of the largest companies on the globe. Unfortunately, the cloud, which is seen as the company’s primary avenue for growth, could also lead to a slow deterioration in some of the firm’s legacy businesses.\nThat the cloud business has been growing at a rapid pace is manifest: IBM can now boast of over 3,200 clients using the firm’s hybrid cloud platform. That is nearly four times the number just prior to the Red Hat acquisition.\nIf management’s claims are accurate, the hybrid cloud platform will create robust growth in the software and services division’s revenues. When combined with the spinoff of Kyndryl’s slow growing managed infrastructure services business, it is reasonable to believe IBM will witness increased growth.\nIBM has a solid balance sheet, a robust yield, and when viewed using PEG ratios as a basis for valuing the stock, the shares are trading at a bit of a discount.\nAll considered, I rate IBM as a BUY.\nI think the worst case short to mid-term scenario is that the company experiences slow growth while investors collect a rather robust dividend.","news_type":1,"symbols_score_info":{"IBM":0.9}},"isVote":1,"tweetType":1,"viewCount":787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":809592134,"gmtCreate":1627376795928,"gmtModify":1703488707453,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Latest&nbsp;","listText":"Latest&nbsp;","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/809592134","repostId":"1154449552","repostType":4,"isVote":1,"tweetType":1,"viewCount":644,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813819894,"gmtCreate":1630167062418,"gmtModify":1676530237453,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Time to some challenge!&nbsp;","listText":"Time to some challenge!&nbsp;","text":"Time to some challenge!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/813819894","repostId":"2162907389","repostType":4,"isVote":1,"tweetType":1,"viewCount":2391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177819608,"gmtCreate":1627194112504,"gmtModify":1703485427676,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Reacted too slowly","listText":"Reacted too slowly","text":"Reacted too slowly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/177819608","repostId":"1176552691","repostType":4,"repost":{"id":"1176552691","kind":"news","pubTimestamp":1627183789,"share":"https://ttm.financial/m/news/1176552691?lang=en_US&edition=fundamental","pubTime":"2021-07-25 11:29","market":"us","language":"en","title":"Is IBM Stock Undervalued Or Overvalued? What To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=1176552691","media":"seekingalpha","summary":"Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.","content":"<p><b>Summary</b></p>\n<ul>\n <li>IBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.</li>\n <li>Prior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 quarters.</li>\n <li>More transparency is needed regarding the Kyndryl spinoff.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c798e0536c6804d44b195f6f349fab5\" tg-width=\"1536\" tg-height=\"1044\" width=\"100%\" height=\"auto\"><span>Ethan Miller/Getty Images News</span></p>\n<p>International Business Machines Corporation (IBM) is a company in transition. Unfortunately for investors, the transition has been in place for the better part of a decade. Those turnaround efforts include investments in cloud computing and artificial intelligence and the divestiture of legacy businesses. While there are now signs of green shoots, it is yet to be seen as to whether the seeds sown have fallen on rocky ground.</p>\n<p>Although the company has a rapidly growing business in hybrid cloud offerings, and a potential growth engine in quantum computing, it faces intense competition in the former industry and uncertain prospects in the latter. Most of the firm’s other businesses are in the doldrums, so IBM’s growth prospects are opaque.</p>\n<p>What is certain is that as of today, IBM has a reasonable and diminishing debt load and strong free cash flow.</p>\n<p>Management is attempting to address growth concerns in part by focusing on the firm’s cloud offerings, while it spins off its managed infrastructure business. That company will be named Kyndryl. However, the debt which the new entity will shoulder, along with the portion of the current dividend that it will carry, has not been divulged.</p>\n<p><b>Recent Quarterly Results</b></p>\n<p>IBM&nbsp;reported&nbsp;Q2 results last Monday. With non-GAAP EPS of $2.33, the company beat estimates by $0.04.</p>\n<p>Revenue of $18.7 billion was flat when adjusted for currency and divestitures.</p>\n<p>The negative side of the report had Systems revenue declining by 7%. However, this was largely due to the normal IBM Z mainframe cycle, down 13% year over year.</p>\n<p>The global financing division, which represents a low single digit percentage of overall revenues, was down 9%. Global technology services, which represents roughly a third of overall revenue and will largely be spun off as Kyndryl, had flattish growth.</p>\n<p>The positive side of the report had Cloud &amp; Cognitive Software cloud revenue up 29% and Global Business Services cloud revenue up 35%. Total cloud revenue of $27 billion increased by 15% over the last 12 months, while cloud revenue grew 13% in the quarter to $7.0 billion.</p>\n<p>Net cash from operating activities hit $17.7 billion, and adjusted free cash flow totaled $11 billion over the last 12 months.</p>\n<p>Since year-end 2020, the company has reduced debt by $6.4 billion.</p>\n<p>Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021.</p>\n<p><b>Where IBM Stands Tall</b></p>\n<p>IBM is viewed by many as at best a third rate IT company and at worst as a dinosaur, headed towards extinction.</p>\n<p>It is evident that the company’s revenues have declined for years; however, to accurately assess the stock, investors must understand that IBM’s legacy businesses have many strengths.</p>\n<p>For example, IBM is the world’s largest IT services company and the dominant provider of mainframes. Among the Fortune 50 companies, 47 are IBM clients.</p>\n<p>Half of the world’s wireless connections are handled by the firm.</p>\n<p>IBM's mainframe systems process nearly 90% of the globe’s credit card transactions, and 97% of the world's largest banks rely on IBM products and services. Consequently, twenty-nine billion ATM transactions are processed annually using IBM systems.</p>\n<p>Eight out of 10 global retailers rely on IBM products and services while 80% of the travel industry's reservations run through IBM systems. That results in 4 billion flight reservations being processed using the company’s IT services.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7ace4f1436fd2697c5ad266b5017e1dd\" tg-width=\"960\" tg-height=\"721\" width=\"100%\" height=\"auto\"><span>Source: Forbes</span></p>\n<p>It is evident that IBM has a massive customer base that provides large scale recurring revenues. In many cases, moving to competitors' offerings would mean risking the transfer of sensitive information, a move many are not willing to take.</p>\n<p>However, with the transition to cloud services and open source software, there is an increased adoption by firms of mix and match IT infrastructures. In turn, this is eroding IBM’s competitive advantage associated with customer switching costs.</p>\n<p><b>The Sources Of Potential Growth</b></p>\n<p>Investors are generally aware of IBM's effort to drive growth through its hybrid cloud offerings. However, when questioned at JPMorgan’s recent investor conference, CFO Jim Kavanaugh&nbsp;provided insight&nbsp;into how hybrid cloud drives revenue in some of IBM’s other divisions.</p>\n<blockquote>\n For every $1 (in business) we land on a hybrid cloud platform, we see $3 to $5 of software drag and $6 to $8 of services drag overall.\n</blockquote>\n<p>Of course, Kavanaugh is using drag to refer to increased revenue in software and services associated with adoption of IBM’s hybrid cloud. If Kavanaugh’s claims are accurate, that means every dollar spent on the company’s hybrid cloud platform translates into $9 to $13 in additional revenue from the firm’s software and services offerings.</p>\n<p>Because hybrid cloud uses a mix of on-premises private cloud and public cloud services, it offers clients a degree of data privacy. This is of particular concern for customers in healthcare and financial services. Consequently, I would posit that IBM might have an advantage in competing with other hybrid cloud providers as it has extensive relationships within those industries.</p>\n<p>I reviewed a variety of prognostications regarding projected growth rates for the hybrid cloud market. The most recent study, which also falls in the middle of other predictions, is by Mordor Intelligence. That firm&nbsp;forecasts&nbsp;a CAGR of 18.73% from 2021 through 2026.</p>\n<p>Investors should be aware that the major operators in this space are Cisco (CSCO), Hewlett Packard (HPE), Amazon (AMZN), Citrix Systems (CTXS), and IBM.</p>\n<p>The following chart provides a record of the firm’s total cloud growth over the last six quarters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5fc85156e70f6caf8ae809f76126a723\" tg-width=\"576\" tg-height=\"336\" width=\"100%\" height=\"auto\"><span>Source: Company reports / Chart by Author</span></p>\n<p>Aside from cloud, there is another source of potential growth, although it is unlikely to materialize soon.</p>\n<p>Early in 2019, IBM&nbsp;introduced&nbsp;the Q System One. IBM Q systems are the world's first quantum computer designed for scientific and commercial use.</p>\n<p>Pardon the pun, but quantum computers represent a quantum leap in technology. Prescient And Strategic Intelligence&nbsp;forecasts&nbsp;a CAGR of 56% for the industry through 2030 with the quantum computer market share reaching nearly $65 billion.</p>\n<p>For additional insights regarding quantum computing and IBM’s position within that industry, I point you to&nbsp;my article, “IBM: Why My Eye Is Fixed On Big Blue.”</p>\n<p><b>Understanding Kyndryl</b></p>\n<p>Once&nbsp;Kyndryl&nbsp;is launched, it will have more than 90,000 employees and more than 4,600 customers in 115 countries. With a $60 billion services backlog, the new entity will begin with projected revenues of $19 billion. At twice the size of its closest competitor, the company will be the world’s largest managed infrastructure services provider.</p>\n<p>The split will&nbsp;transform&nbsp;IBM from a company that pulls half of its revenue from services to a firm with its software and solutions businesses generating over half of its revenue on a recurring basis.</p>\n<p>Global Business Services, which currently constitutes 22% of the company’s revenue, will&nbsp;account&nbsp;for over 40% of sales. Here it is important to note that the division grew revenue by 12% year over year in the last quarter.</p>\n<p>IBM will retain Red Hat and its solution provider business, the systems businesses, and its mission-critical public cloud service, and a software portfolio focused on big data, AI, and security.</p>\n<p>Initially, the two companies will each be the largest customer of the other.</p>\n<p>What remains to be known regarding the spinoff is how much debt each company will shoulder, and the share of the dividend that the companies will pay. Krishna stated the two companies will work together to sustain the current payout level.</p>\n<p><b>Has IBM Turned The Corner?</b></p>\n<p>Anyone who follows IBM knows the company has experienced an extended period of poor results. The following chart provides a record of the firm’s quarterly FCF over the last fourteen quarters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/60cc8b82052f97dd449205999ee30711\" tg-width=\"577\" tg-height=\"337\" width=\"100%\" height=\"auto\"><span>Source: Data from ycharts / chart by author</span></p>\n<p>While this is not proof positive that the company is back on track, the recent trend is at least encouraging.</p>\n<p>In 2020, IBM generated $10.8 billion in free cash flow. Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021. This excludes $3 billion in structural impacts related to the Kyndryl spinoff.</p>\n<p>The CEO&nbsp;recently stated&nbsp;he expects IBM to generate $12 billion to $13 billion in FCF in 2022.</p>\n<p><b>Debt And Dividend</b></p>\n<p>While investors can rightfully complain of a variety of management moves over the years, the firm has maintained a reasonable debt profile while engaging in a number of acquisitions.</p>\n<p>The company has reduced the debt by roughly $18 billion since its peak in mid-2019. IBM maintains an investment level credit rating, and the following chart provides a record of the company’s progress paying down debt of late.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b73e613157c486a5f5e8306546121971\" tg-width=\"1280\" tg-height=\"720\" width=\"100%\" height=\"auto\"><span>Source: IBM Presentation</span></p>\n<p>IBM has a yield of 4.64%, a payout ratio a bit below 61%, and a 5 year dividend growth rate of 4.26%. As previously noted, following the spinoff of Kyndryl, the two companies will team to provide a payout equivalent to the current dividend.</p>\n<p><b>Is IBM Stock Overvalued?</b></p>\n<p>IBM shares trade for $141.13. The average 12 month price target of 8 analysts is $153.50. The price target of the 3 analysts rating the stock since the last earnings report is $151.33.</p>\n<p>IBM has a P/E of 24.05x and a forward P/E of 17.67x. This compares to its five year averages of 16.42x and 13.25x respectively. It is well below the sector average which is in the low thirties for both metrics.</p>\n<p>The 3 to 5 year PEG provided by Seeking Alpha Premium is 1.16x. Schwab calculates a PEG of 1.49x, and Yahoo does not provide a PEG ratio.</p>\n<p>I believe the current P/E ratios for the stock reflect investors anticipating increased growth for IBM once the spinoff is complete. The PEG ratios show the stock is reasonably valued.</p>\n<p><b>Is IBM Stock A Good Long-Term Investment?</b></p>\n<p>IBM has an entrenched but evolving position among many of the largest companies on the globe. Unfortunately, the cloud, which is seen as the company’s primary avenue for growth, could also lead to a slow deterioration in some of the firm’s legacy businesses.</p>\n<p>That the cloud business has been growing at a rapid pace is manifest: IBM can now boast of over 3,200 clients using the firm’s hybrid cloud platform. That is nearly four times the number just prior to the Red Hat acquisition.</p>\n<p>If management’s claims are accurate, the hybrid cloud platform will create robust growth in the software and services division’s revenues. When combined with the spinoff of Kyndryl’s slow growing managed infrastructure services business, it is reasonable to believe IBM will witness increased growth.</p>\n<p>IBM has a solid balance sheet, a robust yield, and when viewed using PEG ratios as a basis for valuing the stock, the shares are trading at a bit of a discount.</p>\n<p>All considered, I rate IBM as a BUY.</p>\n<p>I think the worst case short to mid-term scenario is that the company experiences slow growth while investors collect a rather robust dividend.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is IBM Stock Undervalued Or Overvalued? What To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs IBM Stock Undervalued Or Overvalued? What To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-25 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.\nPrior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 ...</p>\n\n<a href=\"https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM"},"source_url":"https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176552691","content_text":"Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.\nPrior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 quarters.\nMore transparency is needed regarding the Kyndryl spinoff.\n\nEthan Miller/Getty Images News\nInternational Business Machines Corporation (IBM) is a company in transition. Unfortunately for investors, the transition has been in place for the better part of a decade. Those turnaround efforts include investments in cloud computing and artificial intelligence and the divestiture of legacy businesses. While there are now signs of green shoots, it is yet to be seen as to whether the seeds sown have fallen on rocky ground.\nAlthough the company has a rapidly growing business in hybrid cloud offerings, and a potential growth engine in quantum computing, it faces intense competition in the former industry and uncertain prospects in the latter. Most of the firm’s other businesses are in the doldrums, so IBM’s growth prospects are opaque.\nWhat is certain is that as of today, IBM has a reasonable and diminishing debt load and strong free cash flow.\nManagement is attempting to address growth concerns in part by focusing on the firm’s cloud offerings, while it spins off its managed infrastructure business. That company will be named Kyndryl. However, the debt which the new entity will shoulder, along with the portion of the current dividend that it will carry, has not been divulged.\nRecent Quarterly Results\nIBM reported Q2 results last Monday. With non-GAAP EPS of $2.33, the company beat estimates by $0.04.\nRevenue of $18.7 billion was flat when adjusted for currency and divestitures.\nThe negative side of the report had Systems revenue declining by 7%. However, this was largely due to the normal IBM Z mainframe cycle, down 13% year over year.\nThe global financing division, which represents a low single digit percentage of overall revenues, was down 9%. Global technology services, which represents roughly a third of overall revenue and will largely be spun off as Kyndryl, had flattish growth.\nThe positive side of the report had Cloud & Cognitive Software cloud revenue up 29% and Global Business Services cloud revenue up 35%. Total cloud revenue of $27 billion increased by 15% over the last 12 months, while cloud revenue grew 13% in the quarter to $7.0 billion.\nNet cash from operating activities hit $17.7 billion, and adjusted free cash flow totaled $11 billion over the last 12 months.\nSince year-end 2020, the company has reduced debt by $6.4 billion.\nManagement guides for adjusted free cash flow of $11 billion to $12 billion in 2021.\nWhere IBM Stands Tall\nIBM is viewed by many as at best a third rate IT company and at worst as a dinosaur, headed towards extinction.\nIt is evident that the company’s revenues have declined for years; however, to accurately assess the stock, investors must understand that IBM’s legacy businesses have many strengths.\nFor example, IBM is the world’s largest IT services company and the dominant provider of mainframes. Among the Fortune 50 companies, 47 are IBM clients.\nHalf of the world’s wireless connections are handled by the firm.\nIBM's mainframe systems process nearly 90% of the globe’s credit card transactions, and 97% of the world's largest banks rely on IBM products and services. Consequently, twenty-nine billion ATM transactions are processed annually using IBM systems.\nEight out of 10 global retailers rely on IBM products and services while 80% of the travel industry's reservations run through IBM systems. That results in 4 billion flight reservations being processed using the company’s IT services.\nSource: Forbes\nIt is evident that IBM has a massive customer base that provides large scale recurring revenues. In many cases, moving to competitors' offerings would mean risking the transfer of sensitive information, a move many are not willing to take.\nHowever, with the transition to cloud services and open source software, there is an increased adoption by firms of mix and match IT infrastructures. In turn, this is eroding IBM’s competitive advantage associated with customer switching costs.\nThe Sources Of Potential Growth\nInvestors are generally aware of IBM's effort to drive growth through its hybrid cloud offerings. However, when questioned at JPMorgan’s recent investor conference, CFO Jim Kavanaugh provided insight into how hybrid cloud drives revenue in some of IBM’s other divisions.\n\n For every $1 (in business) we land on a hybrid cloud platform, we see $3 to $5 of software drag and $6 to $8 of services drag overall.\n\nOf course, Kavanaugh is using drag to refer to increased revenue in software and services associated with adoption of IBM’s hybrid cloud. If Kavanaugh’s claims are accurate, that means every dollar spent on the company’s hybrid cloud platform translates into $9 to $13 in additional revenue from the firm’s software and services offerings.\nBecause hybrid cloud uses a mix of on-premises private cloud and public cloud services, it offers clients a degree of data privacy. This is of particular concern for customers in healthcare and financial services. Consequently, I would posit that IBM might have an advantage in competing with other hybrid cloud providers as it has extensive relationships within those industries.\nI reviewed a variety of prognostications regarding projected growth rates for the hybrid cloud market. The most recent study, which also falls in the middle of other predictions, is by Mordor Intelligence. That firm forecasts a CAGR of 18.73% from 2021 through 2026.\nInvestors should be aware that the major operators in this space are Cisco (CSCO), Hewlett Packard (HPE), Amazon (AMZN), Citrix Systems (CTXS), and IBM.\nThe following chart provides a record of the firm’s total cloud growth over the last six quarters.\nSource: Company reports / Chart by Author\nAside from cloud, there is another source of potential growth, although it is unlikely to materialize soon.\nEarly in 2019, IBM introduced the Q System One. IBM Q systems are the world's first quantum computer designed for scientific and commercial use.\nPardon the pun, but quantum computers represent a quantum leap in technology. Prescient And Strategic Intelligence forecasts a CAGR of 56% for the industry through 2030 with the quantum computer market share reaching nearly $65 billion.\nFor additional insights regarding quantum computing and IBM’s position within that industry, I point you to my article, “IBM: Why My Eye Is Fixed On Big Blue.”\nUnderstanding Kyndryl\nOnce Kyndryl is launched, it will have more than 90,000 employees and more than 4,600 customers in 115 countries. With a $60 billion services backlog, the new entity will begin with projected revenues of $19 billion. At twice the size of its closest competitor, the company will be the world’s largest managed infrastructure services provider.\nThe split will transform IBM from a company that pulls half of its revenue from services to a firm with its software and solutions businesses generating over half of its revenue on a recurring basis.\nGlobal Business Services, which currently constitutes 22% of the company’s revenue, will account for over 40% of sales. Here it is important to note that the division grew revenue by 12% year over year in the last quarter.\nIBM will retain Red Hat and its solution provider business, the systems businesses, and its mission-critical public cloud service, and a software portfolio focused on big data, AI, and security.\nInitially, the two companies will each be the largest customer of the other.\nWhat remains to be known regarding the spinoff is how much debt each company will shoulder, and the share of the dividend that the companies will pay. Krishna stated the two companies will work together to sustain the current payout level.\nHas IBM Turned The Corner?\nAnyone who follows IBM knows the company has experienced an extended period of poor results. The following chart provides a record of the firm’s quarterly FCF over the last fourteen quarters.\nSource: Data from ycharts / chart by author\nWhile this is not proof positive that the company is back on track, the recent trend is at least encouraging.\nIn 2020, IBM generated $10.8 billion in free cash flow. Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021. This excludes $3 billion in structural impacts related to the Kyndryl spinoff.\nThe CEO recently stated he expects IBM to generate $12 billion to $13 billion in FCF in 2022.\nDebt And Dividend\nWhile investors can rightfully complain of a variety of management moves over the years, the firm has maintained a reasonable debt profile while engaging in a number of acquisitions.\nThe company has reduced the debt by roughly $18 billion since its peak in mid-2019. IBM maintains an investment level credit rating, and the following chart provides a record of the company’s progress paying down debt of late.\nSource: IBM Presentation\nIBM has a yield of 4.64%, a payout ratio a bit below 61%, and a 5 year dividend growth rate of 4.26%. As previously noted, following the spinoff of Kyndryl, the two companies will team to provide a payout equivalent to the current dividend.\nIs IBM Stock Overvalued?\nIBM shares trade for $141.13. The average 12 month price target of 8 analysts is $153.50. The price target of the 3 analysts rating the stock since the last earnings report is $151.33.\nIBM has a P/E of 24.05x and a forward P/E of 17.67x. This compares to its five year averages of 16.42x and 13.25x respectively. It is well below the sector average which is in the low thirties for both metrics.\nThe 3 to 5 year PEG provided by Seeking Alpha Premium is 1.16x. Schwab calculates a PEG of 1.49x, and Yahoo does not provide a PEG ratio.\nI believe the current P/E ratios for the stock reflect investors anticipating increased growth for IBM once the spinoff is complete. The PEG ratios show the stock is reasonably valued.\nIs IBM Stock A Good Long-Term Investment?\nIBM has an entrenched but evolving position among many of the largest companies on the globe. Unfortunately, the cloud, which is seen as the company’s primary avenue for growth, could also lead to a slow deterioration in some of the firm’s legacy businesses.\nThat the cloud business has been growing at a rapid pace is manifest: IBM can now boast of over 3,200 clients using the firm’s hybrid cloud platform. That is nearly four times the number just prior to the Red Hat acquisition.\nIf management’s claims are accurate, the hybrid cloud platform will create robust growth in the software and services division’s revenues. When combined with the spinoff of Kyndryl’s slow growing managed infrastructure services business, it is reasonable to believe IBM will witness increased growth.\nIBM has a solid balance sheet, a robust yield, and when viewed using PEG ratios as a basis for valuing the stock, the shares are trading at a bit of a discount.\nAll considered, I rate IBM as a BUY.\nI think the worst case short to mid-term scenario is that the company experiences slow growth while investors collect a rather robust dividend.","news_type":1,"symbols_score_info":{"IBM":0.9}},"isVote":1,"tweetType":1,"viewCount":787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896868203,"gmtCreate":1628569899302,"gmtModify":1703508301835,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Not a surprise!&nbsp;","listText":"Not a surprise!&nbsp;","text":"Not a surprise!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/896868203","repostId":"1181756731","repostType":4,"repost":{"id":"1181756731","kind":"news","pubTimestamp":1628563781,"share":"https://ttm.financial/m/news/1181756731?lang=en_US&edition=fundamental","pubTime":"2021-08-10 10:49","market":"us","language":"en","title":"3 Vaccine Stocks for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1181756731","media":"The Motley Fool","summary":"Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. W","content":"<p><i><b>Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?</b></i></p>\n<p>Over the last 18 months, COVID-19 has dominated the stock market in general, and vaccine stocks in particular. Companies and governments are trying to vaccinate as many people as possible to minimize the threat of this disease and maybe even eradicate it. That's the here and now, and any news can send vaccine stocks soaring, or crashing, overnight.</p>\n<p>It's hard to imagine what the vaccine stocks will look like 10 years from now. Will COVID-19 still be in the headlines? Or will it recede in importance? A group of Fool contributors suggest you might want to buy shares of&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>,&nbsp;<a href=\"https://laohu8.com/S/PFE\">Pfizer</a> , and&nbsp;<a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a>. Here's why.</p>\n<h3><b>This vaccine superstar will continue to outperform</b></h3>\n<p><b>Patrick Bafuma</b>&nbsp;<b>(Moderna):</b>&nbsp;Talk about setting a high bar with your first drug to market. With&nbsp;$20 billion in advance purchase agreements for 2021, Moderna's COVID-19 vaccine, Spikevax, is set to rival Humira for the best-selling drug in the world in 2021. Not to be proved a fluke, in 2022 this vaccine giant also has $12 billion in advance purchase agreements and another $8 billion in options for Spikevax.</p>\n<p>If there is one thing COVID-19 has demonstrated, it is that this disease is resilient. With New York City set to implement vaccine passports for gyms and indoor dining, other destinations may not be far behind. And with some employers and higher education programs starting to require vaccinations, not to mention the inevitable need for boosters, I believe the demand for jabs of the company's product, which just generated $4.4 billion in second-quarter revenue, will likely remain high.</p>\n<p>We already knew the COVID-19 vaccine was a boon for Moderna. And its flu vaccine is expected to be on the market in 2023 -- a market worth $5 billion to $6 billion annually. And you probably already knew that the mRNA specialist was working toward having a combination flu/respiratory syncytial virus/COVID-19 vaccination. Maybe you even knew that the company's $2 billion to $5 billion cytomegalovirus vaccine candidate is close to entering phase 3 trials. What you may not have known about is CEO Stéphane Bancel's long-term investment in oncology vaccines.</p>\n<p>The company has two exciting cancer vaccines in a 50-50 partnership with&nbsp;<a href=\"https://laohu8.com/S/MRK\">Merck</a> that I am keeping an eye on. These vaccines work by providing patients with an injection of mRNA that gets the patient's immune system to recognize specific abnormalities that are the hallmark of cancerous cells and then get the patient's own immune system to attack the cancer.</p>\n<p>The most advanced product of this collaboration, a \"personal cancer vaccine\" for head and neck squamous cell carcinoma, is currently in phase 2 trials. Thus far in its earlier trials, the treatment has a 50% response rate, more improvements in tumor burden over time, and longer progression-free survival than current standards of care.</p>\n<p>The other Merck-partnered oncology vaccine, while only in phase 1 trials, has a massive addressable market. This one targets mutations within the KRAS gene, with alterations of KRAS present in more than 20% of human cancers. With Moderna's KRAS vaccine covering 80% to 90% of KRAS mutations with its vaccine, this has potential to be another multi-billion-dollar treatment for the company.</p>\n<p>Yes, Spikevax will continue to be the company's cash cow. However, with $12.2 billion in cash and investments, and generating over $4 billion in revenue a quarter, the company has plenty of cash to fuel its research and development pipeline. If we're looking for an innovative vaccine maker to boost the portfolio of healthcare investors for the next 10 years, Moderna has lots of firepower in its pipeline, street credibility, and plenty of cash to make it all happen.</p>\n<h3><b>A $7-billion-a-year opportunity</b></h3>\n<p><b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;Although vaccines have long been a steady source of revenue for multiple big pharmas, investors have historically ignored the value of this particular product category -- that is, until the COVID-19 pandemic hit. The core reason is that vaccines, by and large, tend to be modest revenue generators for their manufacturers, with a few glaring exceptions such as&nbsp;<b>GlaxoSmithKline</b>'s Shingrix and Pfizer's blockbuster Prevnar franchise.</p>\n<p>Another issue is that vaccines have proven to be extremely difficult to develop for some of the most common viral agents. Respiratory syncytial virus, for example, is a seasonal illness that reportedly results in a whopping 58,000 hospitalizations per year in children younger than 5 and 177,000 in people over the age of 65, according to the Centers for Disease Control and Prevention. Yet there are still&nbsp;no fully protective vaccines&nbsp;approved for this large unmet medical need -- despite multiple attempts to develop such a vaccine over the past 60-plus years. Wall Street analysts, in turn, believe that the first company to achieve this lofty goal could be awarded with a product capable of generating over $7 billion per year in sales.</p>\n<p>Which big pharma has the inside track at breaking into this enormous market? As things stand right now, Pfizer is arguably sitting in the catbird seat with its RSV candidate known as RSVpreF. The company recently rolled out exceedingly impressive results for the vaccine in a midstage challenge study in adults under the age of 50. Pfizer has thus decided to advance RSVpreF into a critical phase 3 trial in adults, which is set to kick off next month. Top-line results from this global phase 3 trial ought to be available sometime in the first quarter of 2022.</p>\n<p>If this highly anticipated trial does indeed hit the mark, the pharma titan would almost certainly have its next superstar vaccine product -- possibly making its stock a great buy for long-term investors.</p>\n<h3><b>\"A world without infectious disease\"</b></h3>\n<p><b>Taylor Carmichael</b>&nbsp;<b>(Vir Biotechnology):</b>&nbsp;Vir Bio's mission statement -- \"creating a world without infectious disease\" -- is kind of amazing. If the biotech succeeds in eliminating infectious disease from the planet, it will be the most valuable healthcare company in the world.</p>\n<p>While it's hugely ambitious, it's not impossible. After all, we've largely eliminated some viral diseases like polio and smallpox. And it was vaccines that did it. What Vir is attempting to do, as&nbsp;I understand it, is use the breakthroughs in genomic research to find one-and-done vaccines for diseases like COVID-19, hepatitis B, influenza, and HIV. The company actually has four platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).</p>\n<p>We might ask why this vaccine company isn't a leader in&nbsp;COVID-19 vaccines.&nbsp;Vir Bio may or may not be in last place, but it's way back in the race. The company's vaccine, sotrovimab, is still in its<i>pre-clinical</i>phase.&nbsp;Meanwhile, the mRNA vaccines from Moderna and&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> have been on the market for months. The&nbsp;<a href=\"https://laohu8.com/S/NVAX\">Novavax</a> vaccine has suffered delays, but should be on the market soon. This is a remarkably quick pace, and shareholders of all three companies have been amply rewarded over the last 18 months.</p>\n<p><img src=\"https://static.tigerbbs.com/d0a1bd43968c51fecbafbb7569fc669f\" tg-width=\"720\" tg-height=\"500\" referrerpolicy=\"no-referrer\">NVAXDATA BY&nbsp;YCHARTS</p>\n<p>Compared to the 5,000% return of Novavax, or the 2,000% return of Moderna, or the 1,000% jump BioNTech investors have received, Vir's 200% gain is a little disappointing. (On the other hand, Vir shareholders did six times better than people who invested in an index fund.)</p>\n<p>The main reason Novavax, Moderna, and BioNTech have soared is that all three companies focused on the spike protein of the coronavirus. This has been incredibly successful, creating large numbers of antibodies. If a vaccine produces a large enough level of antibodies, it wards off the disease and keeps people from getting infected.</p>\n<p>What about the future, and all the mutating strains? Historically, the way vaccine companies dealt with mutation in the past, like with the flu, was to vaccinate people again and again. You vaccinate for the known strains and hope the drug will produce enough antibodies and T cells to ward off mutating strains as well. That's why both Novavax and Moderna are pursuing a&nbsp;flu/COVID-19 combo shot&nbsp;-- the plan is for people to take it every year.</p>\n<p>That plan might come to a crashing halt if Vir succeeds with its one-and-done vaccine. While Vir might seem too far back in the race to make any difference, the company has an ace up its sleeve. The Food and Drug Administration has given the company an Emergency Use Authorization to market sotrovimab not as a vaccine, but as a treatment for people who have already been infected with COVID-19. So investors will have real-world data about how the company's drug works.</p>\n<p>Of course the COVID-19 treatment market is vastly smaller than the vaccine market. But what makes Vir so interesting is the company's ultimate focus. Its mission is to eliminate infectious disease from the planet. Today, you might invest in Vir for its COVID-19 treatment. But what's really exciting are the vaccines the company hopes to introduce over the next decade. If Vir successfully removes one major illness from the world, investors will make a lot of money.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Vaccine Stocks for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Vaccine Stocks for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?\nOver the last 18 months, COVID-19 has dominated ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","MRNA":"Moderna, Inc.","MRK":"默沙东","BNTX":"BioNTech SE","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181756731","content_text":"Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?\nOver the last 18 months, COVID-19 has dominated the stock market in general, and vaccine stocks in particular. Companies and governments are trying to vaccinate as many people as possible to minimize the threat of this disease and maybe even eradicate it. That's the here and now, and any news can send vaccine stocks soaring, or crashing, overnight.\nIt's hard to imagine what the vaccine stocks will look like 10 years from now. Will COVID-19 still be in the headlines? Or will it recede in importance? A group of Fool contributors suggest you might want to buy shares of Moderna, Inc., Pfizer , and Vir Biotechnology, Inc.. Here's why.\nThis vaccine superstar will continue to outperform\nPatrick Bafuma (Moderna): Talk about setting a high bar with your first drug to market. With $20 billion in advance purchase agreements for 2021, Moderna's COVID-19 vaccine, Spikevax, is set to rival Humira for the best-selling drug in the world in 2021. Not to be proved a fluke, in 2022 this vaccine giant also has $12 billion in advance purchase agreements and another $8 billion in options for Spikevax.\nIf there is one thing COVID-19 has demonstrated, it is that this disease is resilient. With New York City set to implement vaccine passports for gyms and indoor dining, other destinations may not be far behind. And with some employers and higher education programs starting to require vaccinations, not to mention the inevitable need for boosters, I believe the demand for jabs of the company's product, which just generated $4.4 billion in second-quarter revenue, will likely remain high.\nWe already knew the COVID-19 vaccine was a boon for Moderna. And its flu vaccine is expected to be on the market in 2023 -- a market worth $5 billion to $6 billion annually. And you probably already knew that the mRNA specialist was working toward having a combination flu/respiratory syncytial virus/COVID-19 vaccination. Maybe you even knew that the company's $2 billion to $5 billion cytomegalovirus vaccine candidate is close to entering phase 3 trials. What you may not have known about is CEO Stéphane Bancel's long-term investment in oncology vaccines.\nThe company has two exciting cancer vaccines in a 50-50 partnership with Merck that I am keeping an eye on. These vaccines work by providing patients with an injection of mRNA that gets the patient's immune system to recognize specific abnormalities that are the hallmark of cancerous cells and then get the patient's own immune system to attack the cancer.\nThe most advanced product of this collaboration, a \"personal cancer vaccine\" for head and neck squamous cell carcinoma, is currently in phase 2 trials. Thus far in its earlier trials, the treatment has a 50% response rate, more improvements in tumor burden over time, and longer progression-free survival than current standards of care.\nThe other Merck-partnered oncology vaccine, while only in phase 1 trials, has a massive addressable market. This one targets mutations within the KRAS gene, with alterations of KRAS present in more than 20% of human cancers. With Moderna's KRAS vaccine covering 80% to 90% of KRAS mutations with its vaccine, this has potential to be another multi-billion-dollar treatment for the company.\nYes, Spikevax will continue to be the company's cash cow. However, with $12.2 billion in cash and investments, and generating over $4 billion in revenue a quarter, the company has plenty of cash to fuel its research and development pipeline. If we're looking for an innovative vaccine maker to boost the portfolio of healthcare investors for the next 10 years, Moderna has lots of firepower in its pipeline, street credibility, and plenty of cash to make it all happen.\nA $7-billion-a-year opportunity\nGeorge Budwell (Pfizer): Although vaccines have long been a steady source of revenue for multiple big pharmas, investors have historically ignored the value of this particular product category -- that is, until the COVID-19 pandemic hit. The core reason is that vaccines, by and large, tend to be modest revenue generators for their manufacturers, with a few glaring exceptions such as GlaxoSmithKline's Shingrix and Pfizer's blockbuster Prevnar franchise.\nAnother issue is that vaccines have proven to be extremely difficult to develop for some of the most common viral agents. Respiratory syncytial virus, for example, is a seasonal illness that reportedly results in a whopping 58,000 hospitalizations per year in children younger than 5 and 177,000 in people over the age of 65, according to the Centers for Disease Control and Prevention. Yet there are still no fully protective vaccines approved for this large unmet medical need -- despite multiple attempts to develop such a vaccine over the past 60-plus years. Wall Street analysts, in turn, believe that the first company to achieve this lofty goal could be awarded with a product capable of generating over $7 billion per year in sales.\nWhich big pharma has the inside track at breaking into this enormous market? As things stand right now, Pfizer is arguably sitting in the catbird seat with its RSV candidate known as RSVpreF. The company recently rolled out exceedingly impressive results for the vaccine in a midstage challenge study in adults under the age of 50. Pfizer has thus decided to advance RSVpreF into a critical phase 3 trial in adults, which is set to kick off next month. Top-line results from this global phase 3 trial ought to be available sometime in the first quarter of 2022.\nIf this highly anticipated trial does indeed hit the mark, the pharma titan would almost certainly have its next superstar vaccine product -- possibly making its stock a great buy for long-term investors.\n\"A world without infectious disease\"\nTaylor Carmichael (Vir Biotechnology): Vir Bio's mission statement -- \"creating a world without infectious disease\" -- is kind of amazing. If the biotech succeeds in eliminating infectious disease from the planet, it will be the most valuable healthcare company in the world.\nWhile it's hugely ambitious, it's not impossible. After all, we've largely eliminated some viral diseases like polio and smallpox. And it was vaccines that did it. What Vir is attempting to do, as I understand it, is use the breakthroughs in genomic research to find one-and-done vaccines for diseases like COVID-19, hepatitis B, influenza, and HIV. The company actually has four platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).\nWe might ask why this vaccine company isn't a leader in COVID-19 vaccines. Vir Bio may or may not be in last place, but it's way back in the race. The company's vaccine, sotrovimab, is still in itspre-clinicalphase. Meanwhile, the mRNA vaccines from Moderna and BioNTech SE have been on the market for months. The Novavax vaccine has suffered delays, but should be on the market soon. This is a remarkably quick pace, and shareholders of all three companies have been amply rewarded over the last 18 months.\nNVAXDATA BY YCHARTS\nCompared to the 5,000% return of Novavax, or the 2,000% return of Moderna, or the 1,000% jump BioNTech investors have received, Vir's 200% gain is a little disappointing. (On the other hand, Vir shareholders did six times better than people who invested in an index fund.)\nThe main reason Novavax, Moderna, and BioNTech have soared is that all three companies focused on the spike protein of the coronavirus. This has been incredibly successful, creating large numbers of antibodies. If a vaccine produces a large enough level of antibodies, it wards off the disease and keeps people from getting infected.\nWhat about the future, and all the mutating strains? Historically, the way vaccine companies dealt with mutation in the past, like with the flu, was to vaccinate people again and again. You vaccinate for the known strains and hope the drug will produce enough antibodies and T cells to ward off mutating strains as well. That's why both Novavax and Moderna are pursuing a flu/COVID-19 combo shot -- the plan is for people to take it every year.\nThat plan might come to a crashing halt if Vir succeeds with its one-and-done vaccine. While Vir might seem too far back in the race to make any difference, the company has an ace up its sleeve. The Food and Drug Administration has given the company an Emergency Use Authorization to market sotrovimab not as a vaccine, but as a treatment for people who have already been infected with COVID-19. So investors will have real-world data about how the company's drug works.\nOf course the COVID-19 treatment market is vastly smaller than the vaccine market. But what makes Vir so interesting is the company's ultimate focus. Its mission is to eliminate infectious disease from the planet. Today, you might invest in Vir for its COVID-19 treatment. But what's really exciting are the vaccines the company hopes to introduce over the next decade. If Vir successfully removes one major illness from the world, investors will make a lot of money.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"BNTX":0.9,"MRNA":0.9,"VIR":0.9,"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":2583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887355448,"gmtCreate":1631981462884,"gmtModify":1676530682043,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887355448","repostId":"2168757119","repostType":4,"isVote":1,"tweetType":1,"viewCount":2460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801981924,"gmtCreate":1627479524768,"gmtModify":1703490752094,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801981924","repostId":"1102507343","repostType":4,"isVote":1,"tweetType":1,"viewCount":1754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170751922,"gmtCreate":1626454422266,"gmtModify":1703760575815,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Not for the faint hearted!&nbsp;","listText":"Not for the faint hearted!&nbsp;","text":"Not for the faint hearted!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/170751922","repostId":"1149577900","repostType":4,"isVote":1,"tweetType":1,"viewCount":538,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803214280,"gmtCreate":1627441195740,"gmtModify":1703490029802,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Stay calm people!&nbsp;","listText":"Stay calm people!&nbsp;","text":"Stay calm people!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/803214280","repostId":"2154943718","repostType":4,"repost":{"id":"2154943718","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627440754,"share":"https://ttm.financial/m/news/2154943718?lang=en_US&edition=fundamental","pubTime":"2021-07-28 10:52","market":"hk","language":"en","title":"China state-owned daily urges calm after market rout","url":"https://stock-news.laohu8.com/highlight/detail?id=2154943718","media":"Reuters","summary":"SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday aft","content":"<p>SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday after investors dumped mainland shares for a second day on worries over the impact of tighter government regulations.</p>\n<p>Regulatory moves aimed at the education, property and technology sectors sparked heavy selling this week in Chinese markets, and have left global investors bruised and uncertain over the outlook for investments in Chinese firms.</p>\n<p>In a front page commentary on Wednesday, the state-owned Securities Times said that systemic risks \"do not exist in the A-share market overall.\"</p>\n<p>\"The macroeconomy is still in a steady rebound stage, and short-term fluctuations do not change the long-term positive outlook for A-shares,\" the commentary said.</p>\n<p>\"The recent market decline to some extent reflects misinterpretation of policies and a venting of emotion. Economic fundamentals have not changed and the market will stabilise at any moment.\"</p>\n<p>Other major securities dailies echoed the commentary in market reports.</p>\n<p>In a front page story citing domestic fund managers, the official China Securities Journal said the sell-off was a \"structural adjustment\", a sustained plunge is unlikely and the market does not face systemic risk.</p>\n<p>A story in the state-run Shanghai Securities News quoted domestic analysts as saying that the sell-off would not continue, and that the market will gradually stabilise.</p>\n<p>\"For institutions, the decline brings the opportunity for positioning in high-quality shares,\" it said.</p>\n<p>What started off as a sell-off in shares on Monday had spread into fixed income and foreign exchange markets by Tuesday afternoon, sending the yuan falling through psychologically significant levels and pushing Chinese sovereign bond yields, and the cost of insurance against a default in China's dollar debt, higher.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China state-owned daily urges calm after market rout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina state-owned daily urges calm after market rout\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-28 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday after investors dumped mainland shares for a second day on worries over the impact of tighter government regulations.</p>\n<p>Regulatory moves aimed at the education, property and technology sectors sparked heavy selling this week in Chinese markets, and have left global investors bruised and uncertain over the outlook for investments in Chinese firms.</p>\n<p>In a front page commentary on Wednesday, the state-owned Securities Times said that systemic risks \"do not exist in the A-share market overall.\"</p>\n<p>\"The macroeconomy is still in a steady rebound stage, and short-term fluctuations do not change the long-term positive outlook for A-shares,\" the commentary said.</p>\n<p>\"The recent market decline to some extent reflects misinterpretation of policies and a venting of emotion. Economic fundamentals have not changed and the market will stabilise at any moment.\"</p>\n<p>Other major securities dailies echoed the commentary in market reports.</p>\n<p>In a front page story citing domestic fund managers, the official China Securities Journal said the sell-off was a \"structural adjustment\", a sustained plunge is unlikely and the market does not face systemic risk.</p>\n<p>A story in the state-run Shanghai Securities News quoted domestic analysts as saying that the sell-off would not continue, and that the market will gradually stabilise.</p>\n<p>\"For institutions, the decline brings the opportunity for positioning in high-quality shares,\" it said.</p>\n<p>What started off as a sell-off in shares on Monday had spread into fixed income and foreign exchange markets by Tuesday afternoon, sending the yuan falling through psychologically significant levels and pushing Chinese sovereign bond yields, and the cost of insurance against a default in China's dollar debt, higher.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAAS":"中汽系统"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154943718","content_text":"SHANGHAI, July 28 (Reuters) - A Chinese state-owned securities newspaper urged calm on Wednesday after investors dumped mainland shares for a second day on worries over the impact of tighter government regulations.\nRegulatory moves aimed at the education, property and technology sectors sparked heavy selling this week in Chinese markets, and have left global investors bruised and uncertain over the outlook for investments in Chinese firms.\nIn a front page commentary on Wednesday, the state-owned Securities Times said that systemic risks \"do not exist in the A-share market overall.\"\n\"The macroeconomy is still in a steady rebound stage, and short-term fluctuations do not change the long-term positive outlook for A-shares,\" the commentary said.\n\"The recent market decline to some extent reflects misinterpretation of policies and a venting of emotion. Economic fundamentals have not changed and the market will stabilise at any moment.\"\nOther major securities dailies echoed the commentary in market reports.\nIn a front page story citing domestic fund managers, the official China Securities Journal said the sell-off was a \"structural adjustment\", a sustained plunge is unlikely and the market does not face systemic risk.\nA story in the state-run Shanghai Securities News quoted domestic analysts as saying that the sell-off would not continue, and that the market will gradually stabilise.\n\"For institutions, the decline brings the opportunity for positioning in high-quality shares,\" it said.\nWhat started off as a sell-off in shares on Monday had spread into fixed income and foreign exchange markets by Tuesday afternoon, sending the yuan falling through psychologically significant levels and pushing Chinese sovereign bond yields, and the cost of insurance against a default in China's dollar debt, higher.","news_type":1,"symbols_score_info":{"CAAS":0.9}},"isVote":1,"tweetType":1,"viewCount":754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177839714,"gmtCreate":1627193351038,"gmtModify":1703485412201,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"More install for the year!&nbsp;","listText":"More install for the year!&nbsp;","text":"More install for the year!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/177839714","repostId":"1118041582","repostType":4,"repost":{"id":"1118041582","kind":"news","pubTimestamp":1627175995,"share":"https://ttm.financial/m/news/1118041582?lang=en_US&edition=fundamental","pubTime":"2021-07-25 09:19","market":"us","language":"en","title":"US IPO Week Ahead: 17 IPOs are coming","url":"https://stock-news.laohu8.com/highlight/detail?id=1118041582","media":"Renaissance Capital","summary":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs schedul","content":"<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.</p>\n<p>Long-awaited retail brokerage&nbsp;<b>Robinhood Markets</b>(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.</p>\n<p>Vehicle battery maker&nbsp;<b>Clarios International</b>(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.</p>\n<p>Altice’s ad-tech platform&nbsp;<b>Teads</b>(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.</p>\n<p>Education software provider&nbsp;<b>PowerSchool Holdings</b>(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.</p>\n<p>After withdrawing its IPO attempt in 2018,<b>Dole</b>(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.</p>\n<p>Language learning platform&nbsp;<b>Duolingo</b>(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.</p>\n<p><b>Traeger</b>(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.</p>\n<p>Israeli anti-fraud firm&nbsp;<b>Riskified</b>(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.</p>\n<p>Financial software provider&nbsp;<b>MeridianLink</b>(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.</p>\n<p>Smart home integration system&nbsp;<b>Snap One Holdings</b>(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.</p>\n<p>Specialty funding solutions provider&nbsp;<b>Preston Hollow Community Capital</b>(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.</p>\n<p>Vaccine biotech&nbsp;<b>Icosavax</b>(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.</p>\n<p>Cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.</p>\n<p>Rare disease biotech&nbsp;<b>Rallybio</b>(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.</p>\n<p><b>Ocean Biomedical</b>(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.</p>\n<p>After postponing in November 2020,<b>IN8bio</b>(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.</p>\n<p>Female cancer biotech&nbsp;<b>Context Therapeutics</b>(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.</p>\n<p><img src=\"https://static.tigerbbs.com/4b38a8af5f92621b2633830553616b5d\" tg-width=\"1271\" tg-height=\"702\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5faec597a337345b21c846808295821d\" tg-width=\"1272\" tg-height=\"676\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/021cc62ff4eaabd0b6a7dee91fc0d63e\" tg-width=\"1270\" tg-height=\"483\" referrerpolicy=\"no-referrer\"></p>\n<p><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&amp;P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: 17 IPOs are coming</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: 17 IPOs are coming\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-25 09:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.\nLong-awaited retail brokerage Robinhood Markets(HOOD) plans to raise $2.2 ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CNTX":"Context Therapeutics Inc.",".IXIC":"NASDAQ Composite","HOOD":"Robinhood","SNPO":"Snap One Holdings Corp.","DUOL":"多邻国",".DJI":"道琼斯","COOK":"Traeger Inc. (TGPX Holdings I LLC)","ICVX":"Icosavax, Inc.",".SPX":"S&P 500 Index","PWSC":"PowerSchool Holdings, Inc.","RSKD":"Riskified Ltd.","TEAD":"Teads Holding","FEOVF":"Oceanic Iron Ore Corp.","CADLF":"CADELER AS","DOLE":"都乐食品","MLNK":"MeridianLink, Inc. (ex-Project Angel Parent, LLC)","INAB":"IN8bio, Inc.","RLYB":"Rallybio Corp."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118041582","content_text":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.\nLong-awaited retail brokerage Robinhood Markets(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.\nVehicle battery maker Clarios International(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.\nAltice’s ad-tech platform Teads(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.\nEducation software provider PowerSchool Holdings(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.\nAfter withdrawing its IPO attempt in 2018,Dole(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.\nLanguage learning platform Duolingo(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.\nTraeger(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.\nIsraeli anti-fraud firm Riskified(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.\nFinancial software provider MeridianLink(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.\nSmart home integration system Snap One Holdings(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.\nSpecialty funding solutions provider Preston Hollow Community Capital(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.\nVaccine biotech Icosavax(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.\nCancer biotech Candel Therapeutics(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.\nRare disease biotech Rallybio(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.\nOcean Biomedical(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.\nAfter postponing in November 2020,IN8bio(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.\nFemale cancer biotech Context Therapeutics(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.\n\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.","news_type":1,"symbols_score_info":{"INAB":0.9,"PHCC":0.9,"PWSC":0.9,"RLYB":0.9,"RSKD":0.9,"MLNK":0.9,"TEAD":0.9,"FEOVF":0.9,"DUOL":0.9,"BTRY":0.9,".DJI":0.9,"CNTX":0.9,".IXIC":0.9,"COOK":0.9,"ICVX":0.9,"CADLF":0.9,"HOOD":0.9,".SPX":0.9,"SNPO":0.9,"DOLE":0.9}},"isVote":1,"tweetType":1,"viewCount":440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177830373,"gmtCreate":1627193215692,"gmtModify":1703485409988,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/177830373","repostId":"2153936352","repostType":4,"isVote":1,"tweetType":1,"viewCount":532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171196875,"gmtCreate":1626710605897,"gmtModify":1703763874815,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"A whole new world!&nbsp;","listText":"A whole new world!&nbsp;","text":"A whole new world!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/171196875","repostId":"1146536243","repostType":4,"repost":{"id":"1146536243","kind":"news","pubTimestamp":1626683272,"share":"https://ttm.financial/m/news/1146536243?lang=en_US&edition=fundamental","pubTime":"2021-07-19 16:27","market":"us","language":"en","title":"Morgan Stanley: This Cycle Will Be \"Hotter But Shorter\" Than Usual","url":"https://stock-news.laohu8.com/highlight/detail?id=1146536243","media":"zerohedge","summary":"This cycle is unusual. Most 'normal' cycles are. We think that the recovery is sustainable and more likely to be ‘hotter and shorter’. Sell Treasuries and trust the expansion.","content":"<p>We think that this economic cycle will be normal, strong and short. Each of these assumptions is being hotly debated by the market. Each is key to our investment strategy.</p>\n<p>The debate over cycle 'normalcy' is self-explanatory. The pandemic created, without exaggeration, the single sharpest decline in output in recorded history. Then activity raced back, helped by policy support. The case for viewing this situation as unique, and distinct from other cyclical experiences, is based on the view that a fall and rise this violent never allowed for a traditional 'reset'.</p>\n<p>But 'normal' in markets is a funny concept, with the rough edges of memory often smoothed and polished by the passage of time. The cycle of 2003-07 ended with the largest banking and housing crisis since the Great Depression. The cycle of 1992-2000 ended with the bursting of an enormous equity bubble, widespread accounting fraud and unspeakable tragedy. 'Normal' cycles are nice in theory, harder in practice.</p>\n<p>Instead, let’s consider why we use the term ‘cycle’ at all. Economies and markets tend to follow cyclical patterns, patterns that tend to show up in market performance. It is those patterns we care about, and if they still apply, they can provide a useful guide in uncertain terrain.</p>\n<p>Was last year’s recession preceded by late-cycle conditions such as an inverted yield curve, low volatility, low unemployment, high consumer confidence and narrowing equity market breadth? It was. Did the resulting troughs in equities, credit, yields and yield curves match the usual cadence between market and economic lows? They did. And were the leaders of the ensuing rally the usual early-cycle winners, like small and cyclical stocks, high yield credit and industrial metals? They were.</p>\n<p>If it walks like a duck and quacks like a duck, we think that it’s a normal cycle. Or as normal as these things realistically are.&nbsp;If a lot of 'normal' cycle behavior has played out so far, it should&nbsp;<i>continue</i>&nbsp;to do so.</p>\n<p>Specifically, this relates to patterns of performance as the market recovers. And as that recovery advances, those patterns should shift. As noted by my colleague Michael Wilson, we think that we are moving to a mid-cycle market, despite being just 16 months removed from the lows of economic activity. We see a number of similarities between current conditions and 1H04, a mid-cycle period that followed a large, reflationary rally. And importantly, despite recent fears about growth, we think that the global recovery will keep pushing on (see&nbsp;The Growth Scare Anniversary, July 11, 2021).</p>\n<p>Because one can always find an indicator that fits their particular cycle view, we’ve long been fans of a composite. That’s our ‘cycle model’, which combines ten US metrics across macro, the credit cycle and corporate aggression to gauge where we are in the market cycle. After moving into late-cycle ‘downturn’ in June 2019, and early-cycle ‘repair’ in April 2020, it’s rocketed higher.<b>It has risen so fast that it’s blown right past what should be the next phase ('recovery'), and moved right into ‘expansion’.</b></p>\n<p><img src=\"https://static.tigerbbs.com/41879c4f66b33597ee236bdd52841004\" tg-width=\"904\" tg-height=\"490\" referrerpolicy=\"no-referrer\">Thisis unusual. ‘Expansion’ is meant to capture conditions that are 'better than normal, and improving',<b>and since 1980, it has taken an average of 35 months to get there after 'downturn' ends</b>. Its speedy arrival speaks to a speedy recovery powered by enormous policy support.<b>It also hints at another possibility:&nbsp;this hotter cycle could be shorter.</b>This is our thesis, and it’s showing up in our quantitative measure.</p>\n<p>All this has a number of implications:</p>\n<ul>\n <li><b>The shorter the cycle, the worse for credit relative to other risky assets; credit enjoys fewer of the gains from the 'boom', is exposed if the next downturn is early, and faces more supply as corporate confidence increases</b>. In the ‘expansion’ phase of our cycle model, US IG and HY credit N12M excess returns are 29bp and 161bp worse than average, respectively.</li>\n <li><b>In many of those periods, more mixed credit performance occurs despite default rates remaining low</b>. Investors should try to take default risk over spread risk: our credit strategists like owning CDX HY 0-15%, and hedging with CDX IG payer spreads.</li>\n <li><b>In equities, we think that our model supports more balance in portfolios</b>. We like healthcare in both the US and Europe as a sector with several nice factor exposures: quality, low valuation, high carry and low volatility. Globally, equities in Europe and Japan have tended to outperform 'mid-cycle', and we think that they can do so again.</li>\n <li><b>Interest rates are too pessimistic on the recovery. US 10-year Treasury N12M returns are 97bp worse than average during the ‘expansion’ phase of our cycle model</b>. Guneet Dhingra and our US interest rate strategy team have moved underweight US 10-year Treasuries, and we in turn have moved back underweight government bonds in our global asset allocation.</li>\n</ul>\n<p>This cycle is unusual. Most 'normal' cycles are. We think that the recovery is sustainable and more likely to be ‘hotter and shorter’. Sell Treasuries and trust the expansion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: This Cycle Will Be \"Hotter But Shorter\" Than Usual</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: This Cycle Will Be \"Hotter But Shorter\" Than Usual\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-19 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/morgan-stanley-cycle-will-be-hotter-shorter-usual><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We think that this economic cycle will be normal, strong and short. Each of these assumptions is being hotly debated by the market. Each is key to our investment strategy.\nThe debate over cycle '...</p>\n\n<a href=\"https://www.zerohedge.com/markets/morgan-stanley-cycle-will-be-hotter-shorter-usual\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯","SPY":"标普500ETF",".IXIC":"NASDAQ Composite"},"source_url":"https://www.zerohedge.com/markets/morgan-stanley-cycle-will-be-hotter-shorter-usual","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146536243","content_text":"We think that this economic cycle will be normal, strong and short. Each of these assumptions is being hotly debated by the market. Each is key to our investment strategy.\nThe debate over cycle 'normalcy' is self-explanatory. The pandemic created, without exaggeration, the single sharpest decline in output in recorded history. Then activity raced back, helped by policy support. The case for viewing this situation as unique, and distinct from other cyclical experiences, is based on the view that a fall and rise this violent never allowed for a traditional 'reset'.\nBut 'normal' in markets is a funny concept, with the rough edges of memory often smoothed and polished by the passage of time. The cycle of 2003-07 ended with the largest banking and housing crisis since the Great Depression. The cycle of 1992-2000 ended with the bursting of an enormous equity bubble, widespread accounting fraud and unspeakable tragedy. 'Normal' cycles are nice in theory, harder in practice.\nInstead, let’s consider why we use the term ‘cycle’ at all. Economies and markets tend to follow cyclical patterns, patterns that tend to show up in market performance. It is those patterns we care about, and if they still apply, they can provide a useful guide in uncertain terrain.\nWas last year’s recession preceded by late-cycle conditions such as an inverted yield curve, low volatility, low unemployment, high consumer confidence and narrowing equity market breadth? It was. Did the resulting troughs in equities, credit, yields and yield curves match the usual cadence between market and economic lows? They did. And were the leaders of the ensuing rally the usual early-cycle winners, like small and cyclical stocks, high yield credit and industrial metals? They were.\nIf it walks like a duck and quacks like a duck, we think that it’s a normal cycle. Or as normal as these things realistically are. If a lot of 'normal' cycle behavior has played out so far, it should continue to do so.\nSpecifically, this relates to patterns of performance as the market recovers. And as that recovery advances, those patterns should shift. As noted by my colleague Michael Wilson, we think that we are moving to a mid-cycle market, despite being just 16 months removed from the lows of economic activity. We see a number of similarities between current conditions and 1H04, a mid-cycle period that followed a large, reflationary rally. And importantly, despite recent fears about growth, we think that the global recovery will keep pushing on (see The Growth Scare Anniversary, July 11, 2021).\nBecause one can always find an indicator that fits their particular cycle view, we’ve long been fans of a composite. That’s our ‘cycle model’, which combines ten US metrics across macro, the credit cycle and corporate aggression to gauge where we are in the market cycle. After moving into late-cycle ‘downturn’ in June 2019, and early-cycle ‘repair’ in April 2020, it’s rocketed higher.It has risen so fast that it’s blown right past what should be the next phase ('recovery'), and moved right into ‘expansion’.\nThisis unusual. ‘Expansion’ is meant to capture conditions that are 'better than normal, and improving',and since 1980, it has taken an average of 35 months to get there after 'downturn' ends. Its speedy arrival speaks to a speedy recovery powered by enormous policy support.It also hints at another possibility: this hotter cycle could be shorter.This is our thesis, and it’s showing up in our quantitative measure.\nAll this has a number of implications:\n\nThe shorter the cycle, the worse for credit relative to other risky assets; credit enjoys fewer of the gains from the 'boom', is exposed if the next downturn is early, and faces more supply as corporate confidence increases. In the ‘expansion’ phase of our cycle model, US IG and HY credit N12M excess returns are 29bp and 161bp worse than average, respectively.\nIn many of those periods, more mixed credit performance occurs despite default rates remaining low. Investors should try to take default risk over spread risk: our credit strategists like owning CDX HY 0-15%, and hedging with CDX IG payer spreads.\nIn equities, we think that our model supports more balance in portfolios. We like healthcare in both the US and Europe as a sector with several nice factor exposures: quality, low valuation, high carry and low volatility. Globally, equities in Europe and Japan have tended to outperform 'mid-cycle', and we think that they can do so again.\nInterest rates are too pessimistic on the recovery. US 10-year Treasury N12M returns are 97bp worse than average during the ‘expansion’ phase of our cycle model. Guneet Dhingra and our US interest rate strategy team have moved underweight US 10-year Treasuries, and we in turn have moved back underweight government bonds in our global asset allocation.\n\nThis cycle is unusual. Most 'normal' cycles are. We think that the recovery is sustainable and more likely to be ‘hotter and shorter’. Sell Treasuries and trust the expansion.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582843618871796","authorId":"3582843618871796","name":"Adollar","avatar":"https://static.tigerbbs.com/0b7c3e8d0ea455e203fda09d0d2cffb8","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3582843618871796","idStr":"3582843618871796"},"content":"Changes are happening","text":"Changes are happening","html":"Changes are happening"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171073430,"gmtCreate":1626699826020,"gmtModify":1703763555965,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Turbulent","listText":"Turbulent","text":"Turbulent","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/171073430","repostId":"1111084715","repostType":4,"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561962801944040","authorId":"3561962801944040","name":"mistyzenz","avatar":"https://static.tigerbbs.com/b6ce5e71746857498b3364479f136e14","crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3561962801944040","idStr":"3561962801944040"},"content":"ah, approaching aug","text":"ah, approaching aug","html":"ah, approaching aug"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9032949328,"gmtCreate":1647266968723,"gmtModify":1676534209870,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"No more booster jab pls!&nbsp;","listText":"No more booster jab pls!&nbsp;","text":"No more booster jab pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032949328","repostId":"1186570327","repostType":4,"repost":{"id":"1186570327","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1647265373,"share":"https://ttm.financial/m/news/1186570327?lang=en_US&edition=fundamental","pubTime":"2022-03-14 21:42","market":"us","language":"en","title":"Moderna Shares Soared Nearly 13% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186570327","media":"Tiger Newspress","summary":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology com","content":"<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>&#34;Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,&#34; said Stephen Hoge, M.D., President of Moderna. &#34;This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.&#34;</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>&#34;It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,&#34; said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. &#34;We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.&#34;</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI&#39;s Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill &amp; Melinda Gates Foundation.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shares Soared Nearly 13% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shares Soared Nearly 13% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-14 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>&#34;Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,&#34; said Stephen Hoge, M.D., President of Moderna. &#34;This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.&#34;</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>&#34;It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,&#34; said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. &#34;We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.&#34;</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI&#39;s Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill &amp; Melinda Gates Foundation.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186570327","content_text":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).\"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,\" said Stephen Hoge, M.D., President of Moderna. \"This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.\"The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.\"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,\" said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. \"We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.\"The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803212015,"gmtCreate":1627441017037,"gmtModify":1703490026681,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803212015","repostId":"2154991792","repostType":4,"repost":{"id":"2154991792","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627428087,"share":"https://ttm.financial/m/news/2154991792?lang=en_US&edition=fundamental","pubTime":"2021-07-28 07:21","market":"us","language":"en","title":"Wall St snaps five-day up streak as caution rises before tech earnings, Fed","url":"https://stock-news.laohu8.com/highlight/detail?id=2154991792","media":"Reuters","summary":"NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the t","content":"<p>NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the three major indexes, as investors were cautious before results from top tech and internet names and Wednesday's Federal Reserve announcement.</p>\n<p>The Nasdaq led the day's declines, registering its biggest daily percentage drop since May 12, but the three indexes pared losses heading into the close and ended well off the lows of the session.</p>\n<p>Shares of Apple Inc, Microsoft Corp&nbsp;and Google parent Alphabet Inc , which all reported earnings after the bell, dropped and weighed the most on the Nasdaq and S&amp;P 500 along with Amazon.com Inc , which is expected to report results later this week.</p>\n<p>Also, electric-car maker Tesla Inc fell 2%, a day after it posted a bigger-than-expected second-quarter profit but said a global chip shortage that led to temporary factory shutdowns for the automaker remains serious.</p>\n<p>Shares of the heavily weighted tech and internet companies have run up recently and last week regained leadership in the market, putting their results even more in the spotlight.</p>\n<p>\"Expectations are so high. They're going to have good numbers ... but we are expecting much more or maybe they will talk down the second half of the year,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago.</p>\n<p>Adding to the cautious tone is the outlook for U.S.-listed Chinese stocks, he said. The shares including Baidu extended losses as fears over more regulations in the mainland persisted.</p>\n<p>\"There's a fair amount of (U.S.) investors in those companies,\" Nolte said.</p>\n<p>Uncertainty also rose as the Fed began its two-day meeting, with investors looking for signs on when it intends to begin reining in its massive stimulus program.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 85.79 points, or 0.24%, to 35,058.52, the S&amp;P 500&nbsp;lost 20.84 points, or 0.47%, to 4,401.46 and the Nasdaq Composite &nbsp;dropped 180.14 points, or 1.21%, to 14,660.58.</p>\n<p>Helping to support the Dow, shares of McDonald's Corp&nbsp;rose 1% ahead of its results due before the bell on Wednesday.</p>\n<p>In another sign that investors were in a risk-off mood, defensive sectors such as real estate&nbsp;and utilities&nbsp;were the two best-performing S&amp;P 500 categories for the day, and U.S. Treasuries prices rose.</p>\n<p>Intel Corp&nbsp;shares dropped 2.1% after it said its factories would start building Qualcomm chips and laid out a road map to expand its new foundry business.</p>\n<p>Volume on U.S. exchanges was 10.36 billion shares, compared with the 9.86 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.87-to-1 ratio; on Nasdaq, a 2.65-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 44 new 52-week highs and no new lows; the Nasdaq Composite recorded 39 new highs and 235 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St snaps five-day up streak as caution rises before tech earnings, Fed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St snaps five-day up streak as caution rises before tech earnings, Fed\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-28 07:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the three major indexes, as investors were cautious before results from top tech and internet names and Wednesday's Federal Reserve announcement.</p>\n<p>The Nasdaq led the day's declines, registering its biggest daily percentage drop since May 12, but the three indexes pared losses heading into the close and ended well off the lows of the session.</p>\n<p>Shares of Apple Inc, Microsoft Corp&nbsp;and Google parent Alphabet Inc , which all reported earnings after the bell, dropped and weighed the most on the Nasdaq and S&amp;P 500 along with Amazon.com Inc , which is expected to report results later this week.</p>\n<p>Also, electric-car maker Tesla Inc fell 2%, a day after it posted a bigger-than-expected second-quarter profit but said a global chip shortage that led to temporary factory shutdowns for the automaker remains serious.</p>\n<p>Shares of the heavily weighted tech and internet companies have run up recently and last week regained leadership in the market, putting their results even more in the spotlight.</p>\n<p>\"Expectations are so high. They're going to have good numbers ... but we are expecting much more or maybe they will talk down the second half of the year,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago.</p>\n<p>Adding to the cautious tone is the outlook for U.S.-listed Chinese stocks, he said. The shares including Baidu extended losses as fears over more regulations in the mainland persisted.</p>\n<p>\"There's a fair amount of (U.S.) investors in those companies,\" Nolte said.</p>\n<p>Uncertainty also rose as the Fed began its two-day meeting, with investors looking for signs on when it intends to begin reining in its massive stimulus program.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 85.79 points, or 0.24%, to 35,058.52, the S&amp;P 500&nbsp;lost 20.84 points, or 0.47%, to 4,401.46 and the Nasdaq Composite &nbsp;dropped 180.14 points, or 1.21%, to 14,660.58.</p>\n<p>Helping to support the Dow, shares of McDonald's Corp&nbsp;rose 1% ahead of its results due before the bell on Wednesday.</p>\n<p>In another sign that investors were in a risk-off mood, defensive sectors such as real estate&nbsp;and utilities&nbsp;were the two best-performing S&amp;P 500 categories for the day, and U.S. Treasuries prices rose.</p>\n<p>Intel Corp&nbsp;shares dropped 2.1% after it said its factories would start building Qualcomm chips and laid out a road map to expand its new foundry business.</p>\n<p>Volume on U.S. exchanges was 10.36 billion shares, compared with the 9.86 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.87-to-1 ratio; on Nasdaq, a 2.65-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 44 new 52-week highs and no new lows; the Nasdaq Composite recorded 39 new highs and 235 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154991792","content_text":"NEW YORK, July 27 (Reuters) - U.S. stocks fell on Tuesday, ending a five-day winning streak in the three major indexes, as investors were cautious before results from top tech and internet names and Wednesday's Federal Reserve announcement.\nThe Nasdaq led the day's declines, registering its biggest daily percentage drop since May 12, but the three indexes pared losses heading into the close and ended well off the lows of the session.\nShares of Apple Inc, Microsoft Corp and Google parent Alphabet Inc , which all reported earnings after the bell, dropped and weighed the most on the Nasdaq and S&P 500 along with Amazon.com Inc , which is expected to report results later this week.\nAlso, electric-car maker Tesla Inc fell 2%, a day after it posted a bigger-than-expected second-quarter profit but said a global chip shortage that led to temporary factory shutdowns for the automaker remains serious.\nShares of the heavily weighted tech and internet companies have run up recently and last week regained leadership in the market, putting their results even more in the spotlight.\n\"Expectations are so high. They're going to have good numbers ... but we are expecting much more or maybe they will talk down the second half of the year,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago.\nAdding to the cautious tone is the outlook for U.S.-listed Chinese stocks, he said. The shares including Baidu extended losses as fears over more regulations in the mainland persisted.\n\"There's a fair amount of (U.S.) investors in those companies,\" Nolte said.\nUncertainty also rose as the Fed began its two-day meeting, with investors looking for signs on when it intends to begin reining in its massive stimulus program.\nThe Dow Jones Industrial Average fell 85.79 points, or 0.24%, to 35,058.52, the S&P 500 lost 20.84 points, or 0.47%, to 4,401.46 and the Nasdaq Composite  dropped 180.14 points, or 1.21%, to 14,660.58.\nHelping to support the Dow, shares of McDonald's Corp rose 1% ahead of its results due before the bell on Wednesday.\nIn another sign that investors were in a risk-off mood, defensive sectors such as real estate and utilities were the two best-performing S&P 500 categories for the day, and U.S. Treasuries prices rose.\nIntel Corp shares dropped 2.1% after it said its factories would start building Qualcomm chips and laid out a road map to expand its new foundry business.\nVolume on U.S. exchanges was 10.36 billion shares, compared with the 9.86 billion average for the full session over the last 20 trading days.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.87-to-1 ratio; on Nasdaq, a 2.65-to-1 ratio favored decliners.\nThe S&P 500 posted 44 new 52-week highs and no new lows; the Nasdaq Composite recorded 39 new highs and 235 new lows.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175413435,"gmtCreate":1627046164727,"gmtModify":1703483169835,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Blood bath","listText":"Blood bath","text":"Blood bath","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175413435","repostId":"1193325824","repostType":4,"isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172356250,"gmtCreate":1626939651170,"gmtModify":1703480944310,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;go go go&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;go go go&nbsp;","text":"$Tiger Brokers(TIGR)$ go go go","images":[{"img":"https://static.tigerbbs.com/f08f33078bf98827645845e5e216a71b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172356250","isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":178836113,"gmtCreate":1626796003432,"gmtModify":1703765444856,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Hmmmmm","listText":"Hmmmmm","text":"Hmmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178836113","repostId":"2152657163","repostType":4,"repost":{"id":"2152657163","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1626795120,"share":"https://ttm.financial/m/news/2152657163?lang=en_US&edition=fundamental","pubTime":"2021-07-20 23:32","market":"us","language":"en","title":"AMC to reopen two of the top-grossing movie theaters in Los Angeles","url":"https://stock-news.laohu8.com/highlight/detail?id=2152657163","media":"Dow Jones","summary":"Cinema chain to take over leases for the Grove and the Americana from Pacific Theaters.\n\nAMC jumped ","content":"<blockquote>\n Cinema chain to take over leases for the Grove and the Americana from Pacific Theaters.\n</blockquote>\n<p><b>AMC</b><b>&nbsp;jumped&nbsp;nearly&nbsp;9%&nbsp;in&nbsp;morning&nbsp;trading.</b></p>\n<p><img src=\"https://static.tigerbbs.com/39be46abc677a91e48d845a873557c43\" tg-width=\"824\" tg-height=\"609\" width=\"100%\" height=\"auto\"></p>\n<p>AMC Entertainment Holdings Inc., the world's largest movie-theater chain, is reopening two of the top-grossing theaters in the Los Angeles area, which have been shuttered for more than a year.</p>\n<p>AMC <a href=\"https://laohu8.com/S/AMC\">$(AMC)$</a> said Monday it has reached a long-term lease agreement with privately held real-estate company Caruso, which owns the properties, for the 14-screen Grove Theatre in Los Angeles' Grove shopping center and the 18-screen Americana at Brand Theatre in nearby Glendale, Calif.</p>\n<p>The two theaters were previously run by Pacific Theatres, which announced in April that they, along with 15 other Pacific and ArcLight cinemas nationwide, including Hollywood's iconic Cinerama Dome, would not reopen. The theaters have been closed since early 2020 due to the pandemic.</p>\n<p>AMC said the two theaters will reopen to movie-goers in August. Movie theaters are only now starting to recover from the devastating closures; last week, AMC reported its best weekend for attendance in 16 months, adding that eight of the 10 busiest U.S. movie theaters were run by AMC.</p>\n<p>In 2018, the Grove was the second-highest-grossing movie theater in the Los Angeles area, while the Americana ranked fifth, AMC said Monday.</p>\n<p>AMC may not be done, saying it \"remains in active discussions with other property owners regarding additional currently closed locations.\"</p>\n<p>\"The Grove and The Americana at Brand theatres are among the most successful theatres in the greater Los Angeles area,\" AMC Chief Executive Adam Aron said in a statement. \"AMC is proud to be expanding in the movie-making capital of the world.\"</p>\n<p>AMC shares have been volatile in recent months, and have sunk 41% over the past month. Still, AMC is up more than 1,500% year to date, thanks to the meteoric rise by it and other meme stocks earlier this year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC to reopen two of the top-grossing movie theaters in Los Angeles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC to reopen two of the top-grossing movie theaters in Los Angeles\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-20 23:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n Cinema chain to take over leases for the Grove and the Americana from Pacific Theaters.\n</blockquote>\n<p><b>AMC</b><b>&nbsp;jumped&nbsp;nearly&nbsp;9%&nbsp;in&nbsp;morning&nbsp;trading.</b></p>\n<p><img src=\"https://static.tigerbbs.com/39be46abc677a91e48d845a873557c43\" tg-width=\"824\" tg-height=\"609\" width=\"100%\" height=\"auto\"></p>\n<p>AMC Entertainment Holdings Inc., the world's largest movie-theater chain, is reopening two of the top-grossing theaters in the Los Angeles area, which have been shuttered for more than a year.</p>\n<p>AMC <a href=\"https://laohu8.com/S/AMC\">$(AMC)$</a> said Monday it has reached a long-term lease agreement with privately held real-estate company Caruso, which owns the properties, for the 14-screen Grove Theatre in Los Angeles' Grove shopping center and the 18-screen Americana at Brand Theatre in nearby Glendale, Calif.</p>\n<p>The two theaters were previously run by Pacific Theatres, which announced in April that they, along with 15 other Pacific and ArcLight cinemas nationwide, including Hollywood's iconic Cinerama Dome, would not reopen. The theaters have been closed since early 2020 due to the pandemic.</p>\n<p>AMC said the two theaters will reopen to movie-goers in August. Movie theaters are only now starting to recover from the devastating closures; last week, AMC reported its best weekend for attendance in 16 months, adding that eight of the 10 busiest U.S. movie theaters were run by AMC.</p>\n<p>In 2018, the Grove was the second-highest-grossing movie theater in the Los Angeles area, while the Americana ranked fifth, AMC said Monday.</p>\n<p>AMC may not be done, saying it \"remains in active discussions with other property owners regarding additional currently closed locations.\"</p>\n<p>\"The Grove and The Americana at Brand theatres are among the most successful theatres in the greater Los Angeles area,\" AMC Chief Executive Adam Aron said in a statement. \"AMC is proud to be expanding in the movie-making capital of the world.\"</p>\n<p>AMC shares have been volatile in recent months, and have sunk 41% over the past month. Still, AMC is up more than 1,500% year to date, thanks to the meteoric rise by it and other meme stocks earlier this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152657163","content_text":"Cinema chain to take over leases for the Grove and the Americana from Pacific Theaters.\n\nAMC jumped nearly 9% in morning trading.\n\nAMC Entertainment Holdings Inc., the world's largest movie-theater chain, is reopening two of the top-grossing theaters in the Los Angeles area, which have been shuttered for more than a year.\nAMC $(AMC)$ said Monday it has reached a long-term lease agreement with privately held real-estate company Caruso, which owns the properties, for the 14-screen Grove Theatre in Los Angeles' Grove shopping center and the 18-screen Americana at Brand Theatre in nearby Glendale, Calif.\nThe two theaters were previously run by Pacific Theatres, which announced in April that they, along with 15 other Pacific and ArcLight cinemas nationwide, including Hollywood's iconic Cinerama Dome, would not reopen. The theaters have been closed since early 2020 due to the pandemic.\nAMC said the two theaters will reopen to movie-goers in August. Movie theaters are only now starting to recover from the devastating closures; last week, AMC reported its best weekend for attendance in 16 months, adding that eight of the 10 busiest U.S. movie theaters were run by AMC.\nIn 2018, the Grove was the second-highest-grossing movie theater in the Los Angeles area, while the Americana ranked fifth, AMC said Monday.\nAMC may not be done, saying it \"remains in active discussions with other property owners regarding additional currently closed locations.\"\n\"The Grove and The Americana at Brand theatres are among the most successful theatres in the greater Los Angeles area,\" AMC Chief Executive Adam Aron said in a statement. \"AMC is proud to be expanding in the movie-making capital of the world.\"\nAMC shares have been volatile in recent months, and have sunk 41% over the past month. Still, AMC is up more than 1,500% year to date, thanks to the meteoric rise by it and other meme stocks earlier this year.","news_type":1,"symbols_score_info":{"AMC":0.9,"GRVI":0.9}},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178831498,"gmtCreate":1626795912914,"gmtModify":1703765442573,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Recovering&nbsp;","listText":"Recovering&nbsp;","text":"Recovering","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178831498","repostId":"1127649148","repostType":4,"repost":{"id":"1127649148","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626793055,"share":"https://ttm.financial/m/news/1127649148?lang=en_US&edition=fundamental","pubTime":"2021-07-20 22:57","market":"us","language":"en","title":"U.S. stock main indexes rose more than 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127649148","media":"Tiger Newspress","summary":"(July 20) U.S. stock main indexes rose more than 1% in morning trading.","content":"<p>(July 20)&nbsp;U.S. stock main&nbsp;indexes rose more than 1%&nbsp;in morning trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/e022664a53db67f658ba55350af6aaa5\" tg-width=\"1444\" tg-height=\"170\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/97fe4032e63f9a83cfb2f82950a046ce\" tg-width=\"1866\" tg-height=\"894\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/7704cab75fd884a262bc6756d1f6927a\" tg-width=\"1866\" tg-height=\"927\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/7078c2484f2c1381d606bc832a00fa93\" tg-width=\"1866\" tg-height=\"922\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock main indexes rose more than 1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock main indexes rose more than 1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-20 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(July 20)&nbsp;U.S. stock main&nbsp;indexes rose more than 1%&nbsp;in morning trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/e022664a53db67f658ba55350af6aaa5\" tg-width=\"1444\" tg-height=\"170\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/97fe4032e63f9a83cfb2f82950a046ce\" tg-width=\"1866\" tg-height=\"894\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/7704cab75fd884a262bc6756d1f6927a\" tg-width=\"1866\" tg-height=\"927\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/7078c2484f2c1381d606bc832a00fa93\" tg-width=\"1866\" tg-height=\"922\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127649148","content_text":"(July 20) U.S. stock main indexes rose more than 1% in morning trading.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,"SPY":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":436,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171076193,"gmtCreate":1626699937712,"gmtModify":1703763559915,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Will need to review&nbsp;","listText":"Will need to review&nbsp;","text":"Will need to review","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171076193","repostId":"1165473670","repostType":4,"isVote":1,"tweetType":1,"viewCount":580,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899837205,"gmtCreate":1628172944607,"gmtModify":1703502574255,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Settling time&nbsp;","listText":"Settling time&nbsp;","text":"Settling time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899837205","repostId":"1132594719","repostType":4,"repost":{"id":"1132594719","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628171470,"share":"https://ttm.financial/m/news/1132594719?lang=en_US&edition=fundamental","pubTime":"2021-08-05 21:51","market":"us","language":"en","title":"Coursera fell 3% after soaring 21% yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1132594719","media":"Tiger Newspress","summary":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial r","content":"<p>(Aug 5)&nbsp;Coursera fell 3% after soaring 21% yesterday.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have&nbsp;reported Q2 2021 financial results that look \"mixed\" in the extreme&nbsp;yesterday&nbsp;.</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coursera fell 3% after soaring 21% yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoursera fell 3% after soaring 21% yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 5)&nbsp;Coursera fell 3% after soaring 21% yesterday.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have&nbsp;reported Q2 2021 financial results that look \"mixed\" in the extreme&nbsp;yesterday&nbsp;.</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COUR":"Coursera, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132594719","content_text":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .\nOn the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.\nWait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.\nWhen analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.\nSo in the case of Coursera, analysts forecast that the company would lose $0.11 per sharepro forma.But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company'sGAAPloss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company'spro formaloss for the quarter was only $0.05 per share.\nOr in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"","news_type":1,"symbols_score_info":{"COUR":0.9}},"isVote":1,"tweetType":1,"viewCount":2656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}